. 2014 Feb;384(9938).
doi: 10.1016/S0140-6736(13)62422-8.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar 1 Lijun Zhang 2 Michael Untch 3 Keyur Mehta 4 Joseph P Costantino 5 Norman Wolmark 5 Hervé Bonnefoi 6 David Cameron 7 Luca Gianni 8 Pinuccia Valagussa 9 Sandra M Swain 10 Tatiana Prowell 2 Sibylle Loibl 4 D Lawrence Wickerham 5 Jan Bogaerts 11 Jose Baselga 12 Charles Perou 13 Gideon Blumenthal 2 Jens Blohmer 14 Eleftherios P Mamounas 15 Jonas Bergh 16 Vladimir Semiglazov 17 Robert Justice 2 Holger Eidtmann 18 Soonmyung Paik 5 Martine Piccart 19 Rajeshwari Sridhara 2 Peter A Fasching 20 Leen Slaets 11 Shenghui Tang 2 Bernd Gerber 21 Charles E Geyer 22 Richard Pazdur 2 Nina Ditsch 23 Priya Rastogi 5 Wolfgang Eiermann 23 Gunter von Minckwitz 4 
  • PMID: 24529560
  •     822 citations


Background: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS.

Methods: We searched PubMed, Embase, and Medline for clinical trials of neoadjuvant treatment of breast cancer. To be eligible, studies had to meet three inclusion criteria: include at least 200 patients with primary breast cancer treated with preoperative chemotherapy followed by surgery; have available data for pathological complete response, EFS, and OS; and have a median follow-up of at least 3 years. We compared the three most commonly used definitions of pathological complete response--ypT0 ypN0, ypT0/is ypN0, and ypT0/is--for their association with EFS and OS in a responder analysis. We assessed the association between pathological complete response and EFS and OS in various subgroups. Finally, we did a trial-level analysis to assess whether pathological complete response could be used as a surrogate endpoint for EFS or OS.

Findings: We obtained data from 12 identified international trials and 11 955 patients were included in our responder analysis. Eradication of tumour from both breast and lymph nodes (ypT0 ypN0 or ypT0/is ypN0) was better associated with improved EFS (ypT0 ypN0: hazard ratio [HR] 0·44, 95% CI 0·39-0·51; ypT0/is ypN0: 0·48, 0·43-0·54) and OS (0·36, 0·30-0·44; 0·36, 0·31-0·42) than was tumour eradication from the breast alone (ypT0/is; EFS: HR 0·60, 95% CI 0·55-0·66; OS 0·51, 0·45-0·58). We used the ypT0/is ypN0 definition for all subsequent analyses. The association between pathological complete response and long-term outcomes was strongest in patients with triple-negative breast cancer (EFS: HR 0·24, 95% CI 0·18-0·33; OS: 0·16, 0·11-0·25) and in those with HER2-positive, hormone-receptor-negative tumours who received trastuzumab (EFS: 0·15, 0·09-0·27; OS: 0·08, 0·03, 0·22). In the trial-level analysis, we recorded little association between increases in frequency of pathological complete response and EFS (R(2)=0·03, 95% CI 0·00-0·25) and OS (R(2)=0·24, 0·00-0·70).

Interpretation: Patients who attain pathological complete response defined as ypT0 ypN0 or ypT0/is ypN0 have improved survival. The prognostic value is greatest in aggressive tumour subtypes. Our pooled analysis could not validate pathological complete response as a surrogate endpoint for improved EFS and OS.

Funding: US Food and Drug Administration.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
H Bonnefoi, S Litière, +18 authors, EORTC 10994/BIG 1-00 Study investigators.
Ann Oncol, 2014 Mar 13; 25(6). PMID: 24618153    Free PMC article.
Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Mateusz Opyrchal, Jeffrey L Salisbury, +8 authors, Antonino B D'Assoro.
Int J Oncol, 2014 Jun 28; 45(3). PMID: 24970653    Free PMC article.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, +14 authors, Eric P Winer.
J Clin Oncol, 2014 Aug 06; 33(1). PMID: 25092775    Free PMC article.
Highly Cited.
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Pat Whitworth, Lisette Stork-Sloots, +11 authors, Peter D Beitsch.
Ann Surg Oncol, 2014 Aug 08; 21(10). PMID: 25099655    Free PMC article.
Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.
Nataliya Babyshkina, Elena Malinovskaya, +6 authors, Nadejda Cherdyntseva.
Med Oncol, 2014 Aug 21; 31(9). PMID: 25139196
Genome-driven integrated classification of breast cancer validated in over 7,500 samples.
H Raza Ali, Oscar M Rueda, +4 authors, Carlos Caldas.
Genome Biol, 2014 Aug 29; 15(8). PMID: 25164602    Free PMC article.
Highly Cited.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Judy C Boughey, Linda M McCall, +7 authors, Kelly K Hunt.
Ann Surg, 2014 Sep 10; 260(4). PMID: 25203877    Free PMC article.
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Xiao-song Chen, Ying Yuan, +3 authors, Kun-wei Shen.
PLoS One, 2014 Sep 24; 9(9). PMID: 25247558    Free PMC article.
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
Angelo Gámez-Pozo, Ramón M Pérez Carrión, +20 authors, Pilar Zamora.
PLoS One, 2014 Oct 21; 9(10). PMID: 25330188    Free PMC article.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.
Sonia Pernas Simon.
Ther Adv Med Oncol, 2014 Oct 25; 6(5). PMID: 25342988    Free PMC article.
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Alan P Venook, Maria E Arcila, +15 authors, Marian L Birkeland.
J Natl Compr Canc Netw, 2014 Nov 02; 12(11). PMID: 25361808    Free PMC article.
[Not Available].
David Krug.
Strahlenther Onkol, 2014 Nov 14; 190(10). PMID: 25392872
Molecular Heterogeneity of Triple Negative Breast Cancer.
Vandana G Abramson, Ingrid A Mayer.
Curr Breast Cancer Rep, 2014 Nov 25; 6(3). PMID: 25419441    Free PMC article.
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
Elena García-Martínez, Ginés Luengo Gil, +6 authors, Francisco Ayala de la Peña.
Breast Cancer Res, 2014 Nov 30; 16(6). PMID: 25432519    Free PMC article.
Highly Cited.
Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
D Groheux, S Giacchetti, +5 authors, E Hindié.
Eur J Nucl Med Mol Imaging, 2014 Nov 30; 42(3). PMID: 25432784
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.
Abenaa M Brewster, Mariana Chavez-MacGregor, Powel Brown.
Lancet Oncol, 2014 Dec 03; 15(13). PMID: 25456381    Free PMC article.
Highly Cited. Review.
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
H Bonnefoi, W Jacot, +15 authors, D Cameron.
Ann Oncol, 2014 Dec 04; 26(2). PMID: 25467016    Free PMC article.
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Roisin M Connolly, Jeffrey P Leal, +23 authors, Vered Stearns.
J Nucl Med, 2014 Dec 06; 56(1). PMID: 25476537    Free PMC article.
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Ian J Majewski, Paolo Nuciforo, +18 authors, José Baselga.
J Clin Oncol, 2015 Jan 07; 33(12). PMID: 25559818    Free PMC article.
Highly Cited.
Breast cancer in 2014: A call back to reality!
Fatima Cardoso, Elżbieta Senkus.
Nat Rev Clin Oncol, 2015 Jan 07; 12(2). PMID: 25560532
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
A M Gonzalez-Angulo, N Parinyanitikul, +6 authors, M Chavez-MacGregor.
Br J Cancer, 2015 Jan 15; 112(4). PMID: 25584488    Free PMC article.
Assessing the role of platinum agents in aggressive breast cancers.
William M Sikov.
Curr Oncol Rep, 2015 Feb 11; 17(2). PMID: 25665554
Management of locally advanced breast cancer-perspectives and future directions.
Konstantinos Tryfonidis, Elzbieta Senkus, Maria J Cardoso, Fatima Cardoso.
Nat Rev Clin Oncol, 2015 Feb 11; 12(3). PMID: 25668732
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Flavio Crippa, Roberto Agresti, +13 authors, Filippo de Braud.
Eur J Nucl Med Mol Imaging, 2015 Feb 13; 42(6). PMID: 25673053
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Angela DeMichele, Douglas Yee, +39 authors, Laura J Esserman.
Clin Cancer Res, 2015 Feb 26; 21(13). PMID: 25712686    Free PMC article.
Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Valerie N Barton, Nicholas C D'Amato, +8 authors, Jennifer K Richer.
Mol Cancer Ther, 2015 Feb 26; 14(3). PMID: 25713333    Free PMC article.
Highly Cited.
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Raúl Rincón, Ion Cristóbal, +10 authors, Federico Rojo.
Oncotarget, 2015 Mar 03; 6(6). PMID: 25726524    Free PMC article.
Landscape of neoadjuvant therapy for breast cancer.
Tufia C Haddad, Matthew P Goetz.
Ann Surg Oncol, 2015 Mar 03; 22(5). PMID: 25727557    Free PMC article.
Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
T J A Dekker, A Charehbili, +7 authors, J R Kroep.
Mol Oncol, 2015 Mar 05; 9(6). PMID: 25735561    Free PMC article.
One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
Orsolya Rusz, András Vörös, +6 authors, Zsuzsanna Kahán.
Pathol Oncol Res, 2015 Mar 11; 21(4). PMID: 25753983
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.
Takahiro Kogawa, Tamer M Fouad, +12 authors, Naoto T Ueno.
J Cancer, 2015 Mar 15; 6(4). PMID: 25767600    Free PMC article.
Ki67--no evidence for its use in node-positive breast cancer.
Fabrice Andre, Monica Arnedos, +2 authors, Suzette Delaloge.
Nat Rev Clin Oncol, 2015 Mar 18; 12(5). PMID: 25781576
Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Liang Huang, Sheng Chen, +3 authors, Zhiming Shao.
Int J Nanomedicine, 2015 Mar 21; 10. PMID: 25792830    Free PMC article.
Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
N Maass, F Schütz, +7 authors, M P Lux.
Geburtshilfe Frauenheilkd, 2015 Mar 24; 75(2). PMID: 25797960    Free PMC article.
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
Tari A King, Monica Morrow.
Nat Rev Clin Oncol, 2015 Apr 09; 12(6). PMID: 25850554
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
P G Nuciforo, C Aura, +10 authors, J Baselga.
Ann Oncol, 2015 Apr 09; 26(7). PMID: 25851628    Free PMC article.
Identifying and targeting tumor-initiating cells in the treatment of breast cancer.
Wei Wei, Michael T Lewis.
Endocr Relat Cancer, 2015 Apr 17; 22(3). PMID: 25876646    Free PMC article.
Therapies for triple negative breast cancer.
Eleni Andreopoulou, Sarah J Schweber, Joseph A Sparano, Hayley M McDaid.
Expert Opin Pharmacother, 2015 Apr 18; 16(7). PMID: 25881743    Free PMC article.
Molecular characterization and targeted therapeutic approaches in breast cancer.
Angela Toss, Massimo Cristofanilli.
Breast Cancer Res, 2015 Apr 24; 17. PMID: 25902832    Free PMC article.
Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.
Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano.
Ecancermedicalscience, 2015 May 02; 9. PMID: 25932042    Free PMC article.
Treatment of early-stage HER2+ breast cancer-an evolving field.
Arlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho.
Ecancermedicalscience, 2015 May 02; 9. PMID: 25932047    Free PMC article.
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Florentia Peintinger, Bruno Sinn, +5 authors, W Fraser Symmans.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932963    Free PMC article.
DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.
Wilfried Budach, Christiane Matuschek, +13 authors, Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO).
Strahlenther Onkol, 2015 May 13; 191(8). PMID: 25963557    Free PMC article.
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Kyunghee Park, Moon Ki Choi, +11 authors, Yeon Hee Park.
Oncotarget, 2015 May 27; 6(27). PMID: 26009992    Free PMC article.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
V Bossuyt, E Provenzano, +18 authors, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.
Ann Oncol, 2015 May 29; 26(7). PMID: 26019189    Free PMC article.
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Mark Jesus M Magbanua, Denise M Wolf, +10 authors, Laura J van 't Veer.
Breast Cancer Res, 2015 May 30; 17. PMID: 26021444    Free PMC article.
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer.
I Moya-Horno, J Cortés.
Breast Cancer (Dove Med Press), 2015 Jun 10; 7. PMID: 26056489    Free PMC article.
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
Vito Amoroso, Daniele Generali, +30 authors, Alberto Bottini.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063896    Free PMC article.
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Yeon-Jin Kwon, Kevin Petrie, +18 authors, Samuel Waxman.
Mol Cancer Ther, 2015 Jun 17; 14(8). PMID: 26078298    Free PMC article.
Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.
S Baulies, L Belin, +8 authors, F Reyal.
Br J Cancer, 2015 Jun 17; 113(1). PMID: 26079300    Free PMC article.
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Liang Huang, Sheng Chen, +13 authors, Zhiming Shao.
Oncotarget, 2015 Jun 19; 6(21). PMID: 26084292    Free PMC article.
Targeting and limiting surgery for patients with node-positive breast cancer.
Abigail S Caudle, Henry M Kuerer.
BMC Med, 2015 Jun 26; 13. PMID: 26109042    Free PMC article.
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Shenduo Li, Sturgis Payne, +9 authors, Robin E Bachelder.
Breast Cancer Res, 2015 Jul 05; 17. PMID: 26141457    Free PMC article.
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.
Kathrin Halfter, Nina Ditsch, +9 authors, Behalf of the SpheroNEO Study Group.
BMC Cancer, 2015 Jul 15; 15. PMID: 26169261    Free PMC article.
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Roberto Salgado, Carsten Denkert, +13 authors, Sherene Loi.
JAMA Oncol, 2015 Jul 17; 1(4). PMID: 26181252    Free PMC article.
Highly Cited.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Elena Provenzano, Veerle Bossuyt, +17 authors, Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration.
Mod Pathol, 2015 Jul 25; 28(9). PMID: 26205180
Highly Cited.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Valentina Guarneri, Maria Vittoria Dieci, +13 authors, PierFranco Conte.
Oncologist, 2015 Aug 08; 20(9). PMID: 26245675    Free PMC article.
Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy.
Shravan Kandula, Jeffrey M Switchenko, +5 authors, Mylin A Torres.
Int J Breast Cancer, 2015 Aug 13; 2015. PMID: 26266050    Free PMC article.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Harry D Bear, Gong Tang, +18 authors, Norman Wolmark.
Lancet Oncol, 2015 Aug 15; 16(9). PMID: 26272770    Free PMC article.
The role of taxanes in triple-negative breast cancer: literature review.
Giorgio Mustacchi, Michelino De Laurentiis.
Drug Des Devel Ther, 2015 Aug 15; 9. PMID: 26273192    Free PMC article.
Relevance of tumor-infiltrating lymphocytes in breast cancer.
Sathana Dushyanthen, Paul A Beavis, +5 authors, Sherene Loi.
BMC Med, 2015 Aug 25; 13. PMID: 26300242    Free PMC article.
Highly Cited. Review.
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Giuseppe Aprile, Caterina Fontanella, +10 authors, Gianpiero Fasola.
Oncotarget, 2015 Aug 27; 6(30). PMID: 26308250    Free PMC article.
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy.
Rodolfo Gómez, Carlos Andrés Ossa, +13 authors, Héctor García.
Ecancermedicalscience, 2015 Sep 01; 9. PMID: 26316883    Free PMC article.
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Carlo Palmieri, Iain Rj Macpherson, +14 authors, Sacha J Howell.
Oncotarget, 2015 Sep 04; 7(11). PMID: 26334099    Free PMC article.
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Sasagu Kurozumi, Kenichi Inoue, +5 authors, Tetsunari Oyama.
BMC Cancer, 2015 Sep 09; 15. PMID: 26345461    Free PMC article.
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Eun Sook Ko, Heon Han, +5 authors, Seok Jin Nam.
Korean J Radiol, 2015 Sep 12; 16(5). PMID: 26357493    Free PMC article.
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Lale Kostakoglu, Fenghai Duan, +13 authors, ACRIN 668 Investigative Team.
J Nucl Med, 2015 Sep 12; 56(11). PMID: 26359256    Free PMC article.
CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
Lisa A Carey.
Clin Cancer Res, 2015 Sep 17; 21(18). PMID: 26374072    Free PMC article.
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?
Helena Earl, Elena Provenzano, +4 authors, Louise Hiller.
BMC Med, 2015 Sep 24; 13. PMID: 26391216    Free PMC article.
Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.
Gerd Fastner, Cornelia Hauser-Kronberger, +7 authors, Felix Sedlmayer.
Strahlenther Onkol, 2015 Sep 26; 192(1). PMID: 26403912
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.
Pooja Advani, Lauren Cornell, Saranya Chumsri, Alvaro Moreno-Aspitia.
Breast Cancer (Dove Med Press), 2015 Oct 10; 7. PMID: 26451122    Free PMC article.
Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Yuying Qi, Tinghui Hu, +2 authors, Zuodong Ye.
J Breast Cancer, 2015 Oct 17; 18(3). PMID: 26472971    Free PMC article.
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
E L Korn, M C Sachs, L M McShane.
Ann Oncol, 2015 Oct 23; 27(1). PMID: 26489443    Free PMC article.
SEOM clinical guidelines in early-stage breast cancer 2015.
J A Garcia-Saenz, B Bermejo, +7 authors, E Ciruelos.
Clin Transl Oncol, 2015 Oct 27; 17(12). PMID: 26497356    Free PMC article.
Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer.
Donald A Berry.
Clin Cancer Res, 2015 Oct 30; 22(1). PMID: 26510857    Free PMC article.
Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
Shiwei Liu, Xuening Duan, +8 authors, Yinhua Liu.
Tumour Biol, 2015 Nov 04; 37(4). PMID: 26526577
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Antonio Llombart-Cussac, Begoña Bermejo, +18 authors, Jose Baselga.
Breast Cancer Res Treat, 2015 Nov 06; 154(2). PMID: 26536871    Free PMC article.
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.
Maureen Elizabeth Trudeau, Judith-Anne W Chapman, +9 authors, Amadeo M Parissenti.
Springerplus, 2015 Nov 07; 4. PMID: 26543765    Free PMC article.
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.
Joerg Heil, Sherko Kümmel, +10 authors, Gunter von Minckwitz.
Br J Cancer, 2015 Nov 12; 113(11). PMID: 26554654    Free PMC article.
Targeted Therapies in Triple-Negative Breast Cancer.
Frederik Marmé, Andreas Schneeweiss.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557820    Free PMC article.
The Role of Postmastectomy Radiation Therapy in Patients With Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jose G Bazan, Julia R White.
Semin Radiat Oncol, 2015 Dec 01; 26(1). PMID: 26617210    Free PMC article.
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
Anne-Sophie Hamy, Lisa Belin, +8 authors, Fabien Reyal.
Br J Cancer, 2015 Dec 15; 114(1). PMID: 26657653    Free PMC article.
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Takahiro Kogawa, Tamer M Fouad, +9 authors, Naoto T Ueno.
Oncologist, 2015 Dec 15; 21(1). PMID: 26659222    Free PMC article.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, +4 authors, Sherene Loi.
Nat Rev Clin Oncol, 2015 Dec 17; 13(4). PMID: 26667975
Highly Cited. Review.
Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.
Shariq S Khwaja, Jennifer Ivanovich, +12 authors, Imran Zoberi.
Cancer Med, 2015 Dec 22; 5(2). PMID: 26687192    Free PMC article.
An update in breast cancer screening and management.
Sanjay Warrier, Grace Tapia, David Goltsman, Jane Beith.
Womens Health (Lond), 2015 Dec 23; 12(2). PMID: 26689336    Free PMC article.
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Paul Baron, Peter Beitsch, +13 authors, Pat Whitworth.
Ann Surg Oncol, 2015 Dec 31; 23(5). PMID: 26714960    Free PMC article.
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Tieying Dong, Xinmei Kang, +6 authors, Qingyuan Zhang.
Tumour Biol, 2015 Dec 31; 37(6). PMID: 26715276
Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
Christoph Suppan, Vesna Bjelic-Radisic, +6 authors, Marija Balic.
BMC Cancer, 2015 Dec 31; 15. PMID: 26715527    Free PMC article.
Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Li Cao, Guang-yu Yao, +3 authors, Chang-sheng Ye.
PLoS One, 2015 Dec 31; 10(12). PMID: 26717149    Free PMC article.
Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.
Amar U Kishan, Susan A McCloskey.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753007    Free PMC article.
¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.
David Groheux, David Mankoff, Marc Espié, Elif Hindié.
Eur J Nucl Med Mol Imaging, 2016 Jan 14; 43(5). PMID: 26758726
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Emilio Alba, Ana Lluch, +18 authors, Federico Rojo.
Oncologist, 2016 Jan 21; 21(2). PMID: 26786263    Free PMC article.
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.
Romualdo Barroso-Sousa, Danilo D A Fonseca Reis Silva, Joao Victor Machado Alessi, Max Senna Mano.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823678    Free PMC article.
¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.
Stefanie Avril, Raymond F Muzic, +3 authors, Norbert Avril.
J Nucl Med, 2016 Feb 03; 57 Suppl 1. PMID: 26834099    Free PMC article.
Molecular Imaging of Biomarkers in Breast Cancer.
Gary A Ulaner, Chris C Riedl, +3 authors, Wolfgang Weber.
J Nucl Med, 2016 Feb 03; 57 Suppl 1. PMID: 26834103    Free PMC article.
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.
Samuel A Funt, Paul B Chapman.
Clin Cancer Res, 2016 Feb 05; 22(10). PMID: 26842238    Free PMC article.
Biomarkers of residual disease after neoadjuvant therapy for breast cancer.
Frederique Penault-Llorca, Nina Radosevic-Robin.
Nat Rev Clin Oncol, 2016 Feb 10; 13(8). PMID: 26856744
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Luisa Carbognin, Sara Pilotto, +6 authors, Giampaolo Tortora.
Oncologist, 2016 Feb 13; 21(3). PMID: 26865589    Free PMC article.
Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
Seho Park, Jung Hyun Yoon, +6 authors, Byeong-Woo Park.
PLoS One, 2016 Feb 13; 11(2). PMID: 26866475    Free PMC article.
Patterns in target-directed breast cancer research.
Sofia Torres, Christine Simmons, +3 authors, Maureen Trudeau.
Springerplus, 2016 Feb 16; 5. PMID: 26877907    Free PMC article.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
H Raza Ali, Aliakbar Dariush, +16 authors, Carlos Caldas.
Breast Cancer Res, 2016 Feb 18; 18(1). PMID: 26882907    Free PMC article.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Patrizia Vici, Laura Pizzuti, +30 authors, Filippo Montemurro.
Oncotarget, 2016 Feb 26; 7(14). PMID: 26910921    Free PMC article.
DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.
Patrizia Vici, Simonetta Buglioni, +19 authors, Marcello Maugeri-Saccà.
PLoS One, 2016 Mar 02; 11(3). PMID: 26930412    Free PMC article.
Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort.
Massimiliano D'Aiuto, Andrea Chirico, +9 authors, Antonio Giordano.
Cancer Biol Ther, 2016 Mar 05; 17(5). PMID: 26934127    Free PMC article.
The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Jurui Luo, Zhirui Zhou, +7 authors, Xiaoli Yu.
Medicine (Baltimore), 2016 Mar 05; 95(8). PMID: 26937935    Free PMC article.
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
H Bonsang-Kitzis, B Sadacca, +4 authors, F Reyal.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942074    Free PMC article.
Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Ji Soo Choi, Eun Sook Ko, +2 authors, Seok Jin Nam.
Medicine (Baltimore), 2016 Mar 06; 95(9). PMID: 26945421    Free PMC article.
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Elizabeth A Mittendorf, Jose Vila, +6 authors, Kelly K Hunt.
JAMA Oncol, 2016 Mar 18; 2(7). PMID: 26986538    Free PMC article.
Translating neoadjuvant therapy into survival benefits: one size does not fit all.
Leticia De Mattos-Arruda, Ronglai Shen, Jorge S Reis-Filho, Javier Cortés.
Nat Rev Clin Oncol, 2016 Mar 24; 13(9). PMID: 27000962    Free PMC article.
Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study.
Lori M van Roozendaal, Leonie H M Smit, +6 authors, Marjolein L Smidt.
Breast Cancer Res Treat, 2016 Mar 26; 156(3). PMID: 27013474    Free PMC article.
Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.
Tímea Tőkés, Anna-Mária Tőkés, +5 authors, Magdolna Dank.
Virchows Arch, 2016 Mar 31; 468(6). PMID: 27026269
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Se Hyun Kim, Kyung Hae Jung, +16 authors, Jee Hyun Kim.
Cancer Res Treat, 2016 Oct 19; 48(4). PMID: 27034147    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Role of the androgen receptor in triple-negative breast cancer.
Murtuza Rampurwala, Kari B Wisinski, Ruth O'Regan.
Clin Adv Hematol Oncol, 2016 Apr 09; 14(3). PMID: 27058032    Free PMC article.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
Paula García-Teijido, María Luque Cabal, Ignacio Peláez Fernández, Yolanda Fernández Pérez.
Clin Med Insights Oncol, 2016 Apr 16; 10(Suppl 1). PMID: 27081325    Free PMC article.
Highly Cited. Review.
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Alexander S Brodsky, Jinjun Xiong, +6 authors, Yihong Wang.
BMC Cancer, 2016 Apr 20; 16. PMID: 27090210    Free PMC article.
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Kathrin Halfter, Oliver Hoffmann, +6 authors, Barbara Mayer.
J Transl Med, 2016 May 05; 14(1). PMID: 27142386    Free PMC article.
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population.
Jiayu Wang, Die Sang, +9 authors, Qiao Li.
Medicine (Baltimore), 2016 May 07; 95(18). PMID: 27149453    Free PMC article.
How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Anita Mamtani, Andrea V Barrio, +11 authors, Monica Morrow.
Ann Surg Oncol, 2016 May 11; 23(11). PMID: 27160528    Free PMC article.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Laura Pizzuti, Maddalena Barba, +18 authors, Patrizia Vici.
J Cell Physiol, 2016 May 18; 231(11). PMID: 27187274    Free PMC article.
Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.
JunJie Li, Sheng Chen, +4 authors, ZhiMin Shao.
Oncotarget, 2016 May 19; 8(11). PMID: 27191991    Free PMC article.
A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO).
Nicholas Zdenkowski, Phyllis Butow, +3 authors, Frances M Boyle.
JMIR Res Protoc, 2016 May 22; 5(2). PMID: 27207563    Free PMC article.
Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
Ying L Liu, Anurag Saraf, +4 authors, Eileen P Connolly.
Breast Cancer Res Treat, 2016 May 27; 157(3). PMID: 27225388    Free PMC article.
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
Chul Kim, Vinay Prasad.
Mayo Clin Proc, 2016 May 30;. PMID: 27236424    Free PMC article.
Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.
M Thill, G Pisa, G Isbary.
Geburtshilfe Frauenheilkd, 2016 May 31; 76(5). PMID: 27239064    Free PMC article.
Clinical development of new drug-radiotherapy combinations.
Ricky A Sharma, Ruth Plummer, +37 authors, NCRI CTRad Academia-Pharma Joint Working Group.
Nat Rev Clin Oncol, 2016 Jun 02; 13(10). PMID: 27245279
Highly Cited.
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
Jae-Hyun Park, Miran Jang, +10 authors, Yusuke Nakamura.
Int J Oncol, 2016 Jun 10; 49(2). PMID: 27278091    Free PMC article.
Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals.
Eleftherios Mamounas, Christine Poulos, +3 authors, Vincent Antao.
Ann Surg Oncol, 2016 Jun 11; 23(11). PMID: 27283292    Free PMC article.
Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem.
Breast Cancer (Dove Med Press), 2016 Jun 11; 8. PMID: 27284266    Free PMC article.
Highly Cited.
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
Daniel G Stover, Jonathan L Coloff, +3 authors, Laura M Selfors.
Clin Cancer Res, 2016 Jun 23; 22(24). PMID: 27330058    Free PMC article.
The role of preoperative systemic treatment in patients with breast cancer.
Sylwia Dębska-Szmich, Magdalena Krakowska, +3 authors, Piotr Potemski.
Contemp Oncol (Pozn), 2016 Jul 01; 20(2). PMID: 27358586    Free PMC article.
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Laura M Spring, Arjun Gupta, +5 authors, Aditya Bardia.
JAMA Oncol, 2016 Jul 02; 2(11). PMID: 27367583    Free PMC article.
Highly Cited. Systematic Review.
Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years.
Daniel C McFarland, Jessica Naikan, +3 authors, Amy Tiersten.
J Oncol, 2016 Jul 07; 2016. PMID: 27382369    Free PMC article.
FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sara Sheikhbahaei, Tyler J Trahan, +4 authors, Rathan M Subramaniam.
Oncologist, 2016 Jul 13; 21(8). PMID: 27401897    Free PMC article.
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Anthony Ferrari, Anne Vincent-Salomon, +40 authors, Gilles Thomas.
Nat Commun, 2016 Jul 14; 7. PMID: 27406316    Free PMC article.
Adaptive Randomization of Neratinib in Early Breast Cancer.
John W Park, Minetta C Liu, +41 authors, I-SPY 2 Investigators.
N Engl J Med, 2016 Jul 15; 375(1). PMID: 27406346    Free PMC article.
Highly Cited.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Hope S Rugo, Olufunmilayo I Olopade, +41 authors, I-SPY 2 Investigators.
N Engl J Med, 2016 Jul 15; 375(1). PMID: 27406347    Free PMC article.
Highly Cited.
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
H S Okuma, F Koizumi, +10 authors, K Tamura.
Br J Cancer, 2016 Jul 15; 115(4). PMID: 27415010    Free PMC article.
Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.
Ruo-Xi Wang, Sheng Chen, Xi Jin, Zhi-Ming Shao.
Sci Rep, 2016 Jul 19; 6. PMID: 27426056    Free PMC article.
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yaewon Yang, Seock-Ah Im, +11 authors, Dong-Young Noh.
BMC Cancer, 2016 Jul 23; 16. PMID: 27444430    Free PMC article.
Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent.
Ke-Da Yu, Lei Fan, +3 authors, Zhi-Ming Shao.
Oncotarget, 2016 Jul 23; 8(28). PMID: 27447963    Free PMC article.
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Pin Zhang, Yi Yin, +10 authors, Binghe Xu.
Oncotarget, 2016 Jul 23; 7(37). PMID: 27447966    Free PMC article.
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Erica T Warner, Karla V Ballman, +5 authors, Ann H Partridge.
Breast Cancer Res Treat, 2016 Jul 28; 159(1). PMID: 27449492    Free PMC article.
Attaining pathological complete regression for breast conservation - A pilot experience in a developing country.
E A Sule, M A Nzegwu.
Ann Med Surg (Lond), 2016 Jul 28; 9. PMID: 27453779    Free PMC article.
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Michail Ignatiadis, Dimitrios Zardavas, +18 authors, Ahmad Awada.
PLoS One, 2016 Jul 28; 11(7). PMID: 27454930    Free PMC article.
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.
Ruth Exner, Monika Sachet, +9 authors, Rudolf Oehler.
Cancer Med, 2016 Jul 28; 5(9). PMID: 27457217    Free PMC article.
Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer.
Angela Pennisi, Thomas Kieber-Emmons, Issam Makhoul, Laura Hutchins.
Breast Cancer (Auckl), 2016 Aug 02; 10. PMID: 27478380    Free PMC article.
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
Xi Jin, Yi-Zhou Jiang, +5 authors, Gen-Hong Di.
BMC Cancer, 2016 Aug 09; 16. PMID: 27495967    Free PMC article.
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer.
Giuseppina Rosaria Rita Ricciardi, Tindara Franchina, +3 authors, Vincenzo Adamo.
Onco Targets Ther, 2016 Aug 09; 9. PMID: 27499629    Free PMC article.
Cytotoxic and targeted therapy for hereditary cancers.
Aglaya G Iyevleva, Evgeny N Imyanitov.
Hered Cancer Clin Pract, 2016 Aug 25; 14(1). PMID: 27555886    Free PMC article.
SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.
Lauren L Siewertsz van Reesema, Vasilena Zheleva, +17 authors, Amy H Tang.
EBioMedicine, 2016 Aug 30; 11. PMID: 27569656    Free PMC article.
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Benjamin C Calhoun, Bryce Portier, +5 authors, Larry E Morrison.
BMC Cancer, 2016 Sep 01; 16. PMID: 27576528    Free PMC article.
A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Xi Jin, Yi-Zhou Jiang, +2 authors, Gen-Hong Di.
Sci Rep, 2016 Sep 01; 6. PMID: 27576704    Free PMC article.
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
Xuelei Ma, Xiaoshan Wang, +5 authors, Lei Liu.
PLoS One, 2016 Sep 01; 11(8). PMID: 27579484    Free PMC article.
Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.
Magdalena L Plasilova, Brandon Hayse, +3 authors, Donald R Lannin.
Medicine (Baltimore), 2016 Sep 02; 95(35). PMID: 27583878    Free PMC article.
Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.
Irene L Wapnir, Allison W Kurian, +2 authors, Scarlett L Gomez.
Ann Surg, 2016 Sep 10; 266(2). PMID: 27611617    Free PMC article.
Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Pawel Domagala, Jolanta Hybiak, +3 authors, Jan Lubinski.
Oncotarget, 2016 Sep 15; 7(42). PMID: 27626685    Free PMC article.
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.
Ippei Fukada, Kazuhiro Araki, +10 authors, Yoshinori Ito.
PLoS One, 2016 Sep 16; 11(9). PMID: 27631393    Free PMC article.
Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Yoon Yang Jung, Chang Lim Hyun, +5 authors, Han Suk Ryu.
J Breast Cancer, 2016 Oct 11; 19(3). PMID: 27721875    Free PMC article.
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Michael Ermisch, Anna Bucsics, +28 authors, Brian Godman.
Front Pharmacol, 2016 Oct 14; 7. PMID: 27733828    Free PMC article.
Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy.
Xiao-Shan Cao, Hui-Juan Li, +5 authors, Yong-Sheng Wang.
Oncotarget, 2016 Oct 16; 7(45). PMID: 27738336    Free PMC article.
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
A Hennigs, F Riedel, +9 authors, A Schneeweiss.
Breast Cancer Res Treat, 2016 Nov 03; 160(3). PMID: 27744486    Free PMC article.
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Pat Whitworth, Peter Beitsch, +10 authors, Jennifer Beatty.
Ann Surg Oncol, 2016 Oct 23; 24(3). PMID: 27770345    Free PMC article.
Novel therapeutic strategies for patients with triple-negative breast cancer.
Jun-Fei Zhang, Jia Liu, Yu Wang, Bin Zhang.
Onco Targets Ther, 2016 Nov 02; 9. PMID: 27799799    Free PMC article.
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
Laurence Lousberg, Joëlle Collignon, Guy Jerusalem.
Ther Adv Med Oncol, 2016 Nov 02; 8(6). PMID: 27800032    Free PMC article.
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.
Monica M Rivera Franco, Eucario Leon Rodriguez, +3 authors, Alejandra Armengol Alonso.
Breast Cancer (Auckl), 2016 Nov 15; 10. PMID: 27840578    Free PMC article.
Recent developments and translational aspects in targeted therapy for metastatic breast cancer.
Maximilian Marhold, Rupert Bartsch, Christoph Zielinski.
ESMO Open, 2016 Nov 16; 1(3). PMID: 27843605    Free PMC article.
Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Sanjit Agrawal, Lalit Banswal, +4 authors, Rosina Ahmed.
Indian J Surg Oncol, 2016 Nov 23; 7(4). PMID: 27872526    Free PMC article.
Neoadjuvant chemotherapy in breast cancers.
Shahla Masood.
Womens Health (Lond), 2016 Nov 26; 12(5). PMID: 27885165    Free PMC article.
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Weige Tan, Wei Luo, +6 authors, Chang Gong.
Oncotarget, 2016 Nov 29; 7(52). PMID: 27894097    Free PMC article.
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.
N I Cherny, R Sullivan, +8 authors, E G E de Vries.
ESMO Open, 2016 Dec 03; 1(5). PMID: 27900206    Free PMC article.
I-SPY 2: optimising cancer drug development in the 21st century.
Rupert Bartsch, Evandro de Azambuja.
ESMO Open, 2016 Dec 03; 1(5). PMID: 27900209    Free PMC article.
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
Cigdem Selli, J Michael Dixon, Andrew H Sims.
Breast Cancer Res, 2016 Dec 03; 18(1). PMID: 27903276    Free PMC article.
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Aleix Prat, Ana Lluch, +22 authors, Emilio Alba.
Clin Cancer Res, 2016 Dec 03; 23(12). PMID: 27903675    Free PMC article.
Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.
Sachiko Kiyoto, Yoshifumi Sugawara, +4 authors, Teruhito Mochizuki.
Asia Ocean J Nucl Med Biol, 2016 Dec 03; 4(1). PMID: 27904868    Free PMC article.
Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.
Melissa Pilewskie, Monica Morrow.
JAMA Oncol, 2016 Dec 06; 3(4). PMID: 27918753    Free PMC article.
Neoadjuvant Treatment of Breast Cancer - Advances and Limitations.
Peter A Fasching, Paul Gaß, Alexander Hein.
Breast Care (Basel), 2016 Dec 07; 11(5). PMID: 27920622    Free PMC article.
Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
Hans-Christian Kolberg, Leyla Akpolat-Basci, +3 authors, Cornelia Liedtke.
Breast Care (Basel), 2016 Dec 07; 11(5). PMID: 27920624    Free PMC article.
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Paul Gaß, Peter A Fasching, +47 authors, Christian R Löhberg.
Breast Care (Basel), 2016 Dec 07; 11(5). PMID: 27920623    Free PMC article.
Harnessing benefit from targeting tumor associated carbohydrate antigens.
Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi, +2 authors, Issam Makhoul.
Hum Vaccin Immunother, 2016 Dec 09; 13(2). PMID: 27929800    Free PMC article.
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.
H Raza Ali, Leon Chlon, +2 authors, Carlos Caldas.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959923    Free PMC article.
Highly Cited.
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Tingting Jiang, Weiwei Shi, +8 authors, Christos Hatzis.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959926    Free PMC article.
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence.
Malgorzata Banys-Paluchowski, Natalia Krawczyk, Tanja Fehm.
Front Oncol, 2016 Dec 19; 6. PMID: 27990412    Free PMC article.
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.
Li Yan Lim, Hui Miao, +17 authors, Mikael Hartman.
Cancer Med, 2016 Dec 22; 6(1). PMID: 28000426    Free PMC article.
Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.
Misun Choi, Yeon Hee Park, +4 authors, Eun Yoon Cho.
J Pathol Transl Med, 2016 Dec 26; 51(1). PMID: 28013533    Free PMC article.
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Matthew J Ellis, Vera J Suman, +28 authors, Kelly Hunt.
J Clin Oncol, 2017 Jan 04; 35(10). PMID: 28045625    Free PMC article.
Highly Cited.
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Manabu Futamura, Yasuko Nagao, +11 authors, Kazuhiro Yoshida.
Breast Cancer, 2017 Jan 05; 24(4). PMID: 28050738    Free PMC article.
18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
David Groheux, Antoine Martineau, +5 authors, Charles Lemarignier.
Breast Cancer Res, 2017 Jan 07; 19(1). PMID: 28057031    Free PMC article.
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Yu Zong, Jiayi Wu, Kunwei Shen.
Oncotarget, 2017 Jan 07; 8(10). PMID: 28061451    Free PMC article.
Systematic Review.
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
Geraldine O'Sullivan Coyne, Alice P Chen, Robert Meehan, James H Doroshow.
Drugs, 2017 Jan 13; 77(2). PMID: 28078645    Free PMC article.
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2017 Jan 31; 35(10). PMID: 28135148    Free PMC article.
Highly Cited.
Trends and controversies in multidisciplinary care of the patient with breast cancer.
Laura S Dominici, Monica Morrow, +2 authors, Tari A King.
Curr Probl Surg, 2017 Feb 06; 53(12). PMID: 28160790    Free PMC article.
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Jasmeet C Singh, Anita Mamtani, +14 authors, Chau Dang.
Oncologist, 2017 Feb 09; 22(2). PMID: 28167568    Free PMC article.
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study.
Xiaosong Chen, Guolin Ye, +2 authors, Kunwei Shen.
Chin J Cancer Res, 2017 Feb 09; 28(6). PMID: 28174484    Free PMC article.
MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Mithu Raychaudhuri, Holger Bronger, +3 authors, Stefanie Avril.
Breast Cancer Res Treat, 2017 Feb 10; 162(3). PMID: 28181130    Free PMC article.
Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.
Charles Lemarignier, Antoine Martineau, +4 authors, David Groheux.
Eur J Nucl Med Mol Imaging, 2017 Feb 12; 44(7). PMID: 28188325
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Briete Goorts, Thiemo J A van Nijnatten, +5 authors, Marjolein L Smidt.
Breast Cancer Res Treat, 2017 Feb 17; 163(1). PMID: 28205044    Free PMC article.
Time interval of neoadjuvant chemotherapy to surgery in breast cancer: how long is acceptable?
Tae-Kyung Yoo, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh.
Gland Surg, 2017 Feb 18; 6(1). PMID: 28210546    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis.
Weiqiang Qiao, Linlin Pan, +2 authors, Ming Yang.
PLoS One, 2017 Feb 18; 12(2). PMID: 28212434    Free PMC article.
Biomarkers from in vivo molecular imaging of breast cancer: pretreatment 18F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy.
Francesca Gallivanone, Marta Maria Panzeri, +4 authors, Isabella Castiglioni.
MAGMA, 2017 Mar 02; 30(4). PMID: 28246950    Free PMC article.
Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.
Kristin K Brown, Jessica B Spinelli, John M Asara, Alex Toker.
Cancer Discov, 2017 Mar 04; 7(4). PMID: 28255083    Free PMC article.
Highly Cited.
Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).
Amir Y Sajjadi, Steven J Isakoff, +9 authors, Stefan A Carp.
Biomed Opt Express, 2017 Mar 09; 8(2). PMID: 28270967    Free PMC article.
Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
Fausto Petrelli, Karen Borgonovo, +3 authors, Sandro Barni.
J Gastrointest Oncol, 2017 Mar 11; 8(1). PMID: 28280607    Free PMC article.
Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Priya Rastogi, D Lawrence Wickerham, +3 authors, Norman Wolmark.
Chin Clin Oncol, 2017 Mar 14; 6(1). PMID: 28285537    Free PMC article.
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Zhi-Qiao Xu, Yan Zhang, +4 authors, Xiao-Jing Tie.
BMJ Open, 2017 Mar 16; 7(3). PMID: 28289045    Free PMC article.
Systematic Review.
Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy.
R Schulz-Wendtland, P Dankerl, +11 authors, C R Loehberg.
Geburtshilfe Frauenheilkd, 2017 Mar 24; 77(2). PMID: 28331239    Free PMC article.
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
Katja Pinker, Christopher Riedl, Wolfgang A Weber.
Eur J Nucl Med Mol Imaging, 2017 Apr 01; 44(Suppl 1). PMID: 28361188    Free PMC article.
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Matthew P Goetz, Krishna R Kalari, +25 authors, Judy C Boughey.
J Natl Cancer Inst, 2017 Apr 05; 109(7). PMID: 28376176    Free PMC article.
Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Suyun Chen, Nuhad K Ibrahim, +3 authors, Franklin C Wong.
Oncologist, 2017 Apr 06; 22(5). PMID: 28377466    Free PMC article.
Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
Andrew McGuire, Olga Kalinina, +6 authors, Michael J Kerin.
Breast Cancer Res Treat, 2017 Apr 06; 164(1). PMID: 28378298    Free PMC article.
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Ariella B Hanker, Joan T Garrett, +23 authors, Carlos L Arteaga.
Clin Cancer Res, 2017 Apr 07; 23(15). PMID: 28381415    Free PMC article.
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
Aurelio Bartolome Castrellon, Ihor Pidhorecky, Vicente Valero, Luis Estuardo Raez.
Oncol Rev, 2017 Apr 07; 11(1). PMID: 28382189    Free PMC article.
Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
Jiayu Wang, Shanshan Chen, +8 authors, Qiao Li.
Thorac Cancer, 2017 Apr 13; 8(3). PMID: 28402606    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
Making progress in early breast cancer: Taking time or accepting risk?
Gurdeep S Mannu, David Dodwell.
Eur J Cancer, 2017 Apr 16; 78. PMID: 28411447    Free PMC article.
Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
Antonia K Roseweir, Pamela McCall, +4 authors, Joanne Edwards.
Oncotarget, 2017 Apr 19; 8(23). PMID: 28415597    Free PMC article.
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
A Sheri, I E Smith, +3 authors, M Dowsett.
Breast Cancer Res Treat, 2017 Apr 28; 164(2). PMID: 28447240    Free PMC article.
Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.
Hideyuki Ohzawa, Atsushi Miki, +9 authors, Yoshikazu Yasuda.
Oncol Lett, 2017 Apr 30; 13(3). PMID: 28454317    Free PMC article.
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
H M Earl, L Hiller, +18 authors, ARTemis Investigators Group.
Ann Oncol, 2017 May 02; 28(8). PMID: 28459938    Free PMC article.
Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy.
Yuko Tanabe, Hitoshi Tsuda, +7 authors, Kenji Tamura.
Cancer Sci, 2017 May 06; 108(7). PMID: 28474753    Free PMC article.
The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.
Fangfang Tian, Guohua Shen, +2 authors, Zhiyun Jia.
Eur Radiol, 2017 May 10; 27(11). PMID: 28477166
Systematic Review.
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Donald A Berry, Shouhao Zhou, +7 authors, Jerald P Radich.
JAMA Oncol, 2017 May 12; 3(7). PMID: 28494052    Free PMC article.
Highly Cited.
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Angel L Guerrero-Zotano, Carlos L Arteaga.
Cancer Discov, 2017 May 13; 7(6). PMID: 28495849    Free PMC article.
Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer.
Shelley Henderson, Colin Purdie, +5 authors, Alastair M Thompson.
Eur Radiol, 2017 May 20; 27(11). PMID: 28523352    Free PMC article.
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
Mette S van Ramshorst, Suzana C Teixeira, +9 authors, Marie-Jeanne T Vrancken Peeters.
Cancer Imaging, 2017 May 27; 17(1). PMID: 28545563    Free PMC article.
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Ikuko Sugitani, Shigeto Ueda, +11 authors, Toshiaki Saeki.
Int J Clin Oncol, 2017 May 27; 22(5). PMID: 28547525    Free PMC article.
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Oriana A Petruolo, Melissa Pilewskie, +4 authors, Monica Morrow.
Ann Surg Oncol, 2017 Jun 01; 24(9). PMID: 28560596    Free PMC article.
Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study.
Jianjun Liu, Mingxue Su, +3 authors, Shengying Wang.
Oncotarget, 2017 Jun 08; 8(30). PMID: 28591713    Free PMC article.
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.
Mariana Chavez-MacGregor, Elizabeth A Mittendorf, +3 authors, Sharon H Giordano.
Oncologist, 2017 Jun 09; 22(11). PMID: 28592619    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Judy C Boughey, Karla V Ballman, +5 authors, Kelly K Hunt.
Ann Surg, 2017 Jun 29; 266(4). PMID: 28657941    Free PMC article.
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
B E P J Vriens, I J H Vriens, +9 authors, Breast Cancer Trialists’ Group of the Netherlands (BOOG).
Breast Cancer Res Treat, 2017 Jul 05; 165(3). PMID: 28674765    Free PMC article.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Jordan M Cloyd, Huamin Wang, +18 authors, Matthew H G Katz.
JAMA Surg, 2017 Jul 13; 152(11). PMID: 28700784    Free PMC article.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Miguel Martín, José I Chacón, +19 authors, Silvia Antolín.
Oncologist, 2017 Jul 14; 22(11). PMID: 28701571    Free PMC article.
Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+).
Damian P McCartan, Emily C Zabor, +2 authors, Mahmoud B El-Tamer.
Ann Surg Oncol, 2017 Jul 14; 24(11). PMID: 28702770    Free PMC article.
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, +25 authors, Rita K Schmutzler.
JAMA Oncol, 2017 Jul 18; 3(10). PMID: 28715532    Free PMC article.
Highly Cited.
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
Fresia Pareja, Felipe C Geyer, +3 authors, Jorge S Reis-Filho.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721389    Free PMC article.
Highly Cited. Review.
PIM1: a promising target in patients with triple-negative breast cancer.
Wen Zhao, RuiYue Qiu, Pan Li, Jin Yang.
Med Oncol, 2017 Jul 20; 34(8). PMID: 28721678
Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.
Elizabeth A Mittendorf, Mariana Chavez-MacGregor, +5 authors, Kelly K Hunt.
Ann Surg Oncol, 2017 Jul 21; 24(12). PMID: 28726077    Free PMC article.
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Robert Kemp, Vinay Prasad.
BMC Med, 2017 Jul 22; 15(1). PMID: 28728605    Free PMC article.
Highly Cited.
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
Shetal A Patel, Angela DeMichele.
Curr Oncol Rep, 2017 Jul 25; 19(8). PMID: 28733827
CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.
Jo Anne Zujewski, Lawrence Rubinstein.
NPJ Breast Cancer, 2017 Aug 02; 3. PMID: 28758147    Free PMC article.
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.
Sheheryar Kabraji, Xavier Solé, +6 authors, Sridhar Ramaswamy.
Breast Cancer Res, 2017 Aug 03; 19(1). PMID: 28764807    Free PMC article.
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Hazel Squires, Abdullah Pandor, +5 authors, Lynda Wyld.
Pharmacoeconomics, 2017 Aug 05; 36(1). PMID: 28770452
Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
C Marín Hernández, A Piñero Madrona, +4 authors, P Parrilla Paricio.
Clin Transl Oncol, 2017 Aug 09; 20(4). PMID: 28785911
The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
O Burgués, Mª Á López-García, +4 authors, V Peg.
Clin Transl Oncol, 2017 Aug 11; 20(3). PMID: 28795336
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Jianbin Li, Shusen Wang, +11 authors, Zefei Jiang.
Oncologist, 2017 Aug 12; 22(11). PMID: 28798274    Free PMC article.
Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
Chao You, Weijun Peng, +7 authors, Yajia Gu.
Transl Oncol, 2017 Aug 15; 10(5). PMID: 28806712    Free PMC article.
Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients.
Gene Y Cho, Lucas Gennaro, +8 authors, Sunitha B Thakur.
Eur J Radiol Open, 2017 Sep 01; 4. PMID: 28856177    Free PMC article.
Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
Valentina Iotti, Sara Ravaioli, +15 authors, Pierpaolo Pattacini.
Breast Cancer Res, 2017 Sep 13; 19(1). PMID: 28893303    Free PMC article.
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Carmen Herrero-Vicent, Angel Guerrero, +7 authors, Amparo Ruiz-Simón.
Ecancermedicalscience, 2017 Sep 14; 11. PMID: 28900472    Free PMC article.
The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.
Viriya Kaewkangsadan, Chandan Verma, +4 authors, Oleg Eremin.
J Immunol Res, 2017 Sep 16; 2017. PMID: 28913366    Free PMC article.
Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.
Lori F Gentile, George Plitas, +3 authors, Andrea V Barrio.
Ann Surg Oncol, 2017 Sep 17; 24(13). PMID: 28916978    Free PMC article.
Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer.
Mehmet Salih İyikesici, Abdul Kadir Slocum, +3 authors, Thomas N Seyfried.
Cureus, 2017 Sep 20; 9(7). PMID: 28924531    Free PMC article.
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Siker Kimbung, Ida Markholm, +14 authors, PROMIX Trialists Group.
Int J Cancer, 2017 Sep 25; 142(3). PMID: 28940389    Free PMC article.
High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.
Kun-Ming Rau, Yu-Li Su, +6 authors, Chien-Ting Liu.
Mol Med Rep, 2017 Sep 26; 16(5). PMID: 28944897    Free PMC article.
Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry.
Kiho You, Sungmin Park, +6 authors, Jeong Eon Lee.
J Breast Cancer, 2017 Oct 04; 20(3). PMID: 28970856    Free PMC article.
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.
Audrey Monneur, Anthony Goncalves, +11 authors, François Bertucci.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029489    Free PMC article.
Targeting the androgen receptor in triple-negative breast cancer: current perspectives.
Alain Mina, Rachel Yoder, Priyanka Sharma.
Onco Targets Ther, 2017 Oct 17; 10. PMID: 29033586    Free PMC article.
Drug development for noncastrate prostate cancer in a changed therapeutic landscape.
Min Yuen Teo, Matthew J O'Shaughnessy, +2 authors, Howard I Scher.
Nat Rev Clin Oncol, 2017 Oct 19; 15(3). PMID: 29039422    Free PMC article.
Treatment of triple-negative breast cancer with Chinese herbal medicine: A prospective cohort study protocol.
Hui Meng, Nan Peng, +4 authors, Xiaomin Wang.
Medicine (Baltimore), 2017 Nov 03; 96(44). PMID: 29095272    Free PMC article.
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.
Manuela Milani, Sergio Venturini, +14 authors, Giandomenico Roviello.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108271    Free PMC article.
Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.
Liheng Zhou, Shuguang Xu, +7 authors, Jinsong Lu.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108309    Free PMC article.
Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer.
Jiantang Zhang, Fangmeng Fu, +6 authors, Chuan Wang.
Oncotarget, 2017 Nov 09; 8(46). PMID: 29113420    Free PMC article.
New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.
Benjamin Sadacca, Anne-Sophie Hamy, +6 authors, Fabien Reyal.
Sci Rep, 2017 Nov 11; 7(1). PMID: 29123141    Free PMC article.
Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis.
Xuan Li, Danian Dai, +2 authors, Weidong Wei.
World J Surg Oncol, 2017 Dec 01; 15(1). PMID: 29183336    Free PMC article.
Systematic Review.
Pre-operative Endocrine Therapy.
Laura M Arthur, Arran K Turnbull, Lucy R Khan, J Michael Dixon.
Curr Breast Cancer Rep, 2017 Dec 05; 9(4). PMID: 29201277    Free PMC article.
Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.
John Virostko, Allison Hainline, +9 authors, Anna G Sorace.
J Med Imaging (Bellingham), 2017 Dec 05; 5(1). PMID: 29201942    Free PMC article.
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.
Mateusz Opyrchal, Malgorzata Gil, +11 authors, Antonino B D'Assoro.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207686    Free PMC article.
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Jia Yu, Bo Qin, +27 authors, Liewei Wang.
Breast Cancer Res, 2017 Dec 08; 19(1). PMID: 29212525    Free PMC article.
Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
Jacques Raphael, S Nofech-Mozes, +2 authors, S Gandhi.
Pathol Oncol Res, 2017 Dec 10; 25(4). PMID: 29222623
Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Nataliya Babyshkina, Marina Zavyalova, +6 authors, Nadejda Cherdyntseva.
Mol Cell Biochem, 2017 Dec 13; 444(1-2). PMID: 29230610
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
S M Reddy, C H Barcenas, +5 authors, V Valero.
Br J Cancer, 2017 Dec 14; 118(1). PMID: 29235566    Free PMC article.
Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.
Liang Huang, Qi Liu, Sheng Chen, Zhiming Shao.
Onco Targets Ther, 2017 Dec 15; 10. PMID: 29238206    Free PMC article.
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet Oncol, 2017 Dec 16; 19(1). PMID: 29242041    Free PMC article.
Highly Cited. Review.
Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular.
Nancy Reynoso-Noverón, Cynthia Villarreal-Garza, +9 authors, Alejandro Mohar.
J Glob Oncol, 2017 Dec 16; 3(6). PMID: 29244990    Free PMC article.
Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.
Teng Zhu, Fangping Xu, +5 authors, Kun Wang.
Oncotarget, 2017 Dec 20; 8(60). PMID: 29254147    Free PMC article.
Intrinsic subtypes and bladder cancer metastasis.
David J McConkey, Woonyoung Choi, Andrea Ochoa, Colin P N Dinney.
Asian J Urol, 2016 Oct 01; 3(4). PMID: 29264194    Free PMC article.
Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.
Marcelo Sobral-Leite, Esther H Lips, +7 authors, Rosane Vianna-Jorge.
PLoS One, 2017 Dec 22; 12(12). PMID: 29267323    Free PMC article.
Update Breast Cancer 2017 - Implementation of Novel Therapies.
Michael P Lux, Wolfgang Janni, +18 authors, Peter A Fasching.
Geburtshilfe Frauenheilkd, 2017 Dec 23; 77(12). PMID: 29269955    Free PMC article.
Tumor Heterogeneity in Breast Cancer.
Gulisa Turashvili, Edi Brogi.
Front Med (Lausanne), 2017 Dec 26; 4. PMID: 29276709    Free PMC article.
Highly Cited. Review.
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Yuka Asano, Shinichiro Kashiwagi, +11 authors, Masaichi Ohira.
BMC Cancer, 2017 Dec 29; 17(1). PMID: 29282021    Free PMC article.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Luca Gianni, Mauro Mansutti, +18 authors, Ignacio Tusquets.
JAMA Oncol, 2018 Jan 13; 4(3). PMID: 29327055    Free PMC article.
Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Yu Jin Kim, Minjung Sung, +4 authors, Yoon-La Choi.
Cancer Biol Ther, 2018 Jan 16; 19(4). PMID: 29333926    Free PMC article.
Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome.
Christos Davatzikos, Saima Rathore, +22 authors, Despina Kontos.
J Med Imaging (Bellingham), 2018 Jan 18; 5(1). PMID: 29340286    Free PMC article.
Highly Cited.
The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy.
Nelli Roininen, Kirsi-Maria Haapasaari, Peeter Karihtala.
Oxid Med Cell Longev, 2018 Jan 20; 2017. PMID: 29348788    Free PMC article.
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
Lu Zhang, Qingzhao Yu, +5 authors, Tekeda Ferguson.
Breast Cancer Res Treat, 2018 Jan 26; 169(1). PMID: 29368311    Free PMC article.
Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Ziyu Li, Fei Shan, +8 authors, Jiafu Ji.
PLoS One, 2018 Jan 26; 13(1). PMID: 29370182    Free PMC article.
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
Isabel Echavarria, Sara López-Tarruella, +19 authors, Miguel Martin.
Clin Cancer Res, 2018 Jan 31; 24(8). PMID: 29378733    Free PMC article.
Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.
David Krug, René Baumann, +11 authors, Rolf Sauer.
Strahlenther Onkol, 2018 Feb 01; 194(7). PMID: 29383405
Systematic Review.
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).
Arlindo R Ferreira, Otto Metzger-Filho, Roberta M B Sarmento, José Bines.
Front Oncol, 2018 Feb 09; 7. PMID: 29416986    Free PMC article.
Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study.
Kwonoh Park, Miyoung Woo, +5 authors, Sung-Bae Kim.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423090    Free PMC article.
Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.
Paul Ruff, Herbert Cubasch, +7 authors, Alfred I Neugut.
Cancer Manag Res, 2018 Feb 23; 10. PMID: 29467582    Free PMC article.
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Xiujuan Wu, Peng Tang, +6 authors, Yi Zhang.
Nat Commun, 2018 Feb 28; 9(1). PMID: 29483583    Free PMC article.
Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example.
Barbara Fingleton, Kelly Lange, +2 authors, Board of the Metastasis Research Society.
Clin Exp Metastasis, 2018 Feb 28; 34(8). PMID: 29484519
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo.
Ann Surg Oncol, 2018 Mar 04; 25(7). PMID: 29500764    Free PMC article.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Does Chemotherapy Induce Metastases?
Bruce A Chabner.
Oncologist, 2018 Mar 11; 23(3). PMID: 29523674    Free PMC article.
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.
Takayuki Ueno, Shigehira Saji, +12 authors, Masakazu Toi.
ESMO Open, 2018 Mar 14; 3(2). PMID: 29531841    Free PMC article.
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
Nicholas McAndrew, Angela DeMichele.
J Target Ther Cancer, 2018 Mar 27; 7(1). PMID: 29577076    Free PMC article.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Frankie Ann Holmes, Beth A Hellerstedt, +11 authors, Joyce O'Shaughnessy.
Cancer Med, 2018 Mar 28; 7(6). PMID: 29582557    Free PMC article.
My burning issues in the neoadjuvant treatment for breast cancer.
Elisabeth S Bergen, Rupert Bartsch.
Memo, 2018 Apr 03; 11(1). PMID: 29606978    Free PMC article.
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Yuka Asano, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
J Transl Med, 2018 Apr 05; 16(1). PMID: 29615063    Free PMC article.
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
David Groheux, L Biard, +9 authors, P de Cremoux.
Eur J Nucl Med Mol Imaging, 2018 Apr 05; 45(8). PMID: 29616304
Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Gabriel von Waldenfels, Sibylle Loibl, +11 authors, Jens-Uwe Blohmer.
Oncotarget, 2018 Apr 11; 9(20). PMID: 29632634    Free PMC article.
Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Shelley A Henderson, Nazleen Muhammad Gowdh, +5 authors, Sarah Vinnicombe.
Br J Radiol, 2018 Apr 12; 91(1087). PMID: 29641224    Free PMC article.
Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.
Marco Galvez, Carlos A Castaneda, +10 authors, Henry L Gomez.
World J Clin Oncol, 2018 Apr 14; 9(2). PMID: 29651385    Free PMC article.
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Anita A Turk, Kari B Wisinski.
Cancer, 2018 Apr 17; 124(12). PMID: 29660759    Free PMC article.
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Anna Weiss, Sami I Bashour, +2 authors, Nuhad K Ibrahim.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661243    Free PMC article.
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
Patricia de Cremoux, Lucie Biard, +9 authors, David Groheux.
Oncotarget, 2018 Apr 18; 9(23). PMID: 29662649    Free PMC article.
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis.
Curr Treat Options Oncol, 2018 Apr 18; 19(5). PMID: 29663173
Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Gorka Ruiz de Garibay, Francesca Mateo, +19 authors, Miguel Angel Pujana.
Dis Model Mech, 2018 Apr 19; 11(5). PMID: 29666142    Free PMC article.
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients.
Hikmat Abdel-Razeq, Salwa S Saadeh, +6 authors, Dalia Rimawi.
Onco Targets Ther, 2018 Apr 27; 11. PMID: 29695917    Free PMC article.
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
G S Bhattacharyya, M Walia, +6 authors, P M Parikh.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721485    Free PMC article.
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim.
ESMO Open, 2018 May 17; 3(Suppl 1). PMID: 29765774    Free PMC article.
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.
James N Ingle, Krishna R Kalari, +16 authors, Richard M Weinshilboum.
Pharmacogenet Genomics, 2018 May 17; 28(6). PMID: 29768301    Free PMC article.
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Peter A Fasching, Sibylle Loibl, +24 authors, Fergus J Couch.
J Clin Oncol, 2018 May 24; 36(22). PMID: 29791287    Free PMC article.
Highly Cited.
ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
Isabelle Veys, Catalin-Florin Pop, +7 authors, Pierre Bourgeois.
PLoS One, 2018 May 26; 13(5). PMID: 29799849    Free PMC article.
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
H Arias-Pulido, A Cimino-Mathews, +8 authors, S Fiering.
Breast Cancer Res Treat, 2018 Jun 03; 171(2). PMID: 29858752    Free PMC article.
Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice.
Anna Marlene Rüland, Friederike Hagemann, +8 authors, Sherko Kümmel.
Breast Care (Basel), 2018 Jun 12; 13(2). PMID: 29887788    Free PMC article.
Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Quing Zhu, Susan Tannenbaum, +10 authors, Kert Sabbath.
Breast Cancer Res, 2018 Jun 15; 20(1). PMID: 29898762    Free PMC article.
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Angela Santonja, Alfonso Sánchez-Muñoz, +18 authors, Emilio Alba.
Oncotarget, 2018 Jun 15; 9(41). PMID: 29899867    Free PMC article.
Advances in the systemic treatment of triple-negative breast cancer.
J M Lebert, R Lester, +2 authors, J McCarthy.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910657    Free PMC article.
Highly Cited. Review.
The evolution of biosimilars in oncology, with a focus on trastuzumab.
N A Nixon, M B Hannouf, S Verma.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910660    Free PMC article.
Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model.
Brittany A Simone, Ajay Palagani, +8 authors, Nicole L Simone.
Cell Cycle, 2018 Jun 19; 17(13). PMID: 29912618    Free PMC article.
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Valentina Cocciolone, Katia Cannita, +16 authors, Corrado Ficorella.
Oncotarget, 2018 Jun 26; 9(44). PMID: 29937992    Free PMC article.
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
M T Tetzlaff, J L Messina, +20 authors, R A Scolyer.
Ann Oncol, 2018 Jun 27; 29(8). PMID: 29945191    Free PMC article.
Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy.
M R Boland, T P McVeigh, +7 authors, R S Prichard.
BJS Open, 2018 Jun 29; 1(2). PMID: 29951604    Free PMC article.
Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.
David Krug, René Baumann, +12 authors, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO).
Strahlenther Onkol, 2018 Jul 06; 194(9). PMID: 29974132
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rubén Rodríguez Bautista, Alette Ortega Gómez, +4 authors, Oscar Arrieta.
Clin Epigenetics, 2018 Jul 10; 10. PMID: 29983835    Free PMC article.
Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.
Erqi L Pollom, Yushen Qian, +5 authors, C Jillian Tsai.
Int J Cancer, 2018 Jul 12; 143(12). PMID: 29992582    Free PMC article.
The search for surrogate endpoints for immunotherapy trials.
Marc Buyse, Tomasz Burzykowski, Everardo D Saad.
Ann Transl Med, 2018 Jul 20; 6(11). PMID: 30023394    Free PMC article.
Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
Nadia Harbeck.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034548    Free PMC article.
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Maki Tanioka, Cheng Fan, +18 authors, Charles M Perou.
Clin Cancer Res, 2018 Jul 25; 24(21). PMID: 30037817    Free PMC article.
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Kathy D Miller, Anne O'Neill, +12 authors, George W Sledge.
J Clin Oncol, 2018 Jul 25; 36(25). PMID: 30040523    Free PMC article.
Surrogate endpoints in early prostate cancer research.
Scott Williams.
Transl Androl Urol, 2018 Jul 28; 7(3). PMID: 30050805    Free PMC article.
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.
Paul Gass, Michael Untch, +18 authors, Naiba Nabieva.
Geburtshilfe Frauenheilkd, 2018 Jul 31; 78(7). PMID: 30057427    Free PMC article.
Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
Marie Viala, Akiko Chiba, +6 authors, William Jacot.
BMC Cancer, 2018 Aug 01; 18(1). PMID: 30060745    Free PMC article.
The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis.
Yanal Alnimer, Zakaria Hindi, Khalil Katato.
Breast Cancer (Auckl), 2018 Aug 10; 12. PMID: 30090017    Free PMC article.
APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yoshitaka Fujiki, Yutaka Yamamoto, +5 authors, Hirotaka Iwase.
Oncotarget, 2018 Aug 11; 9(55). PMID: 30093965    Free PMC article.
Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
Jianguo Lai, Hongli Wang, +2 authors, Zihao Pan.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122984    Free PMC article.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Judy C Boughey, Michael D Alvarado, +36 authors, and I-SPY 2 Investigators.
NPJ Breast Cancer, 2018 Aug 23; 4. PMID: 30131975    Free PMC article.
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.
Inga H Rye, Anne Trinh, +8 authors, Hege G Russnes.
Mol Oncol, 2018 Aug 23; 12(11). PMID: 30133130    Free PMC article.
Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era.
Naomi Nakajima, Masahiko Oguchi, +7 authors, Shinji Ohno.
Adv Radiat Oncol, 2018 Sep 12; 3(3). PMID: 30202796    Free PMC article.
Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.
Yu-Tuan Wu, Zhou Xu, +9 authors, Ling-Quan Kong.
J Cancer, 2018 Sep 14; 9(17). PMID: 30210640    Free PMC article.
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Laura Spring, Andrzej Niemierko, +14 authors, Aditya Bardia.
Breast Cancer Res Treat, 2018 Sep 17; 172(3). PMID: 30220055    Free PMC article.
Current concepts and future directions in neoadjuvant chemotherapy of breast cancer.
Rupert Bartsch, Elisabeth Bergen, Arik Galid.
Memo, 2018 Sep 18; 11(3). PMID: 30220926    Free PMC article.
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy.
Rupert Bartsch, Elisabeth Bergen.
Memo, 2018 Sep 18; 11(3). PMID: 30220927    Free PMC article.
Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy.
Wataru Goto, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
ESMO Open, 2018 Sep 21; 3(6). PMID: 30233820    Free PMC article.
Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
Pegah Sasanpour, Saleh Sandoughdaran, Alireza Mosavi-Jarrahi, Mona Malekzadeh.
Asian Pac J Cancer Prev, 2018 Sep 27; 19(9). PMID: 30255695    Free PMC article.
Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment.
Concetta Elisa Onesti, Claire Josse, +4 authors, Guy Jerusalem.
Oncotarget, 2018 Sep 29; 9(72). PMID: 30263098    Free PMC article.
Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?
Anya Romanoff, Emily C Zabor, +4 authors, Andrea V Barrio.
Cancer, 2018 Oct 12; 124(22). PMID: 30307616    Free PMC article.
Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis.
Yu-Tuan Wu, Zhou Xu, +8 authors, Ling-Quan Kong.
Ther Clin Risk Manag, 2018 Oct 13; 14. PMID: 30310287    Free PMC article.
From Standard of Care to the Neoadjuvant Model as an Innovative Platform for Exploring Promising Combinations in Breast Cancer.
Cristina Saura.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319324    Free PMC article.
Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer.
Cristina Pernaut, Flora Lopez, Eva Ciruelos.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319326    Free PMC article.
Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.
Santiago Escrivá-de-Romaní, Miriam Arumí, Esther Zamora, Meritxell Bellet.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319327    Free PMC article.
Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto.
Int J Surg Case Rep, 2018 Oct 22; 52. PMID: 30343261    Free PMC article.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging.
Hamed Vavadi, Atahar Mostafa, +7 authors, Quing Zhu.
J Biomed Opt, 2018 Oct 24; 24(2). PMID: 30350491    Free PMC article.
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.
Ashley J Schlafstein, Allison E Withers, +10 authors, David S Yu.
Int J Breast Cancer, 2018 Nov 09; 2018. PMID: 30405916    Free PMC article.
The value of magnetic resonance imaging to diagnose pathological complete response of rectal cancer after therapy: A protocol for meta-analysis.
Mei Zhang, Jipin Li, +5 authors, Jiancheng Wang.
Medicine (Baltimore), 2018 Nov 10; 97(43). PMID: 30412091    Free PMC article.
Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Jing-Min Dong, Hong-Xia Wang, +8 authors, Bin Wang.
Medicine (Baltimore), 2018 Nov 10; 97(43). PMID: 30412117    Free PMC article.
Clinical implications of changes in the diversity of c-MYC copy number variation after neoadjuvant chemotherapy in breast cancer.
Yul Ri Chung, Hyun Jeong Kim, +2 authors, So Yeon Park.
Sci Rep, 2018 Nov 14; 8(1). PMID: 30420657    Free PMC article.
Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.
Javier Cuello-López, Ana Fidalgo-Zapata, Laura López-Agudelo, Elsa Vásquez-Trespalacios.
PLoS One, 2018 Nov 15; 13(11). PMID: 30427884    Free PMC article.
Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.
Eliana La Rocca, Michela Dispinzieri, +5 authors, Maria Carmen De Santis.
Med Oncol, 2018 Nov 18; 36(1). PMID: 30443687
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.
Begoña Martin-Castillo, Sonia Pernas, +25 authors, Javier A Menendez.
Oncotarget, 2018 Nov 28; 9(86). PMID: 30479698    Free PMC article.
Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
Peng Huang, Deng-Jie Ouyang, +9 authors, Wen-Jun Yi.
Cell Commun Signal, 2018 Dec 01; 16(1). PMID: 30497491    Free PMC article.
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.
Achim Wöckel, Michael P Lux, +17 authors, Hans-Christian Kolberg.
Geburtshilfe Frauenheilkd, 2018 Dec 01; 78(11). PMID: 30498278    Free PMC article.
Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy.
Mark K Farrugia, Sinjen Wen, Geraldine M Jacobson, Mohamad Adham Salkeni.
World J Nucl Med, 2018 Dec 07; 17(4). PMID: 30505226    Free PMC article.
Whole genome sequencing of breast cancer.
Maria Rossing, Claus Storgaard Sørensen, Bent Ejlertsen, Finn Cilius Nielsen.
APMIS, 2019 Jan 29; 127(5). PMID: 30689231    Free PMC article.
The use of 3'-deoxy-3'-18F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy.
Benjamin E Ueberroth, Jawana M Lawhorn-Crews, +5 authors, Anthony F Shields.
Ann Nucl Med, 2019 Feb 28; 33(6). PMID: 30810980    Free PMC article.
Local treatment of oligometastatic disease: current role.
Moritz T Winkelmann, Stephan Clasen, Philippe L Pereira, Rüdiger Hoffmann.
Br J Radiol, 2019 May 28; 92(1100). PMID: 31124700    Free PMC article.
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Sara A Hurvitz, Miguel Martin, +18 authors, Dennis Slamon.
J Clin Oncol, 2019 Jun 04; 37(25). PMID: 31157583    Free PMC article.
Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
Devon Livingston-Rosanoff, Jessica Schumacher, +4 authors, Lee G Wilke.
Clin Breast Cancer, 2019 Jul 14; 19(6). PMID: 31300338    Free PMC article.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Sandra M Swain, Gong Tang, +8 authors, Norman Wolmark.
Breast Cancer Res Treat, 2019 Aug 21; 178(2). PMID: 31428908    Free PMC article.
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.
Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci.
Oncologist, 2019 Aug 25; 24(11). PMID: 31444294    Free PMC article.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Sonia Pernas, Anna Petit, +13 authors, Aleix Prat.
Front Oncol, 2019 Aug 27; 9. PMID: 31448227    Free PMC article.
Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.
Jasmin Zeindler, Savas Deniz Soysal, +6 authors, Christian Kurzeder.
Front Med (Lausanne), 2019 Oct 02; 6. PMID: 31572728    Free PMC article.
Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen.
Soo Yeon Baek, Ji Yeong Kwon, +12 authors, Jong Won Lee.
J Breast Cancer, 2019 Oct 11; 22(3). PMID: 31598339    Free PMC article.
Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer.
Qiong Fang, Jiahui Huang, +3 authors, Beiwen Wu.
J Breast Cancer, 2019 Oct 11; 22(3). PMID: 31598340    Free PMC article.
Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype- Breast Cancer.
Hyung Suk Kim, Tae Kyung Yoo, Woo Chan Park, Byung Joo Chae.
J Breast Cancer, 2019 Oct 11; 22(3). PMID: 31598341    Free PMC article.
Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis.
Wen-Pei Wu, Hwa-Koon Wu, +6 authors, Hung-Wen Lai.
PLoS One, 2019 Oct 11; 14(10). PMID: 31600220    Free PMC article.
A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence.
Marcia V Fournier, Edward C Goodwin, +3 authors, Adam M Brufsky.
Sci Rep, 2019 Oct 18; 9(1). PMID: 31619719    Free PMC article.
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Hans-Christian Kolberg, Marco Colleoni, +5 authors, Vladimir Hanes.
Target Oncol, 2019 Oct 18; 14(6). PMID: 31620980    Free PMC article.
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.
Jiani Wang, Binghe Xu.
Signal Transduct Target Ther, 2019 Oct 23; 4. PMID: 31637013    Free PMC article.
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Zhimin Shao, Da Pang, +18 authors, Jennifer Eng-Wong.
JAMA Oncol, 2019 Oct 28; 6(3). PMID: 31647503    Free PMC article.
Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
Florian Schütz, Peter A Fasching, +16 authors, Volkmar Müller.
Geburtshilfe Frauenheilkd, 2019 Oct 28; 79(10). PMID: 31656318    Free PMC article.
Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Florian Heitz, Sherko Kümmel, +9 authors, Sibylle Loibl.
Geburtshilfe Frauenheilkd, 2019 Oct 28; 79(10). PMID: 31656321    Free PMC article.
Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center.
Erika Marina Solla Negrão, Almir Galvão Vieira Bitencourt, Juliana Alves de Souza, Elvira Ferreira Marques.
Radiol Bras, 2019 Oct 28; 52(5). PMID: 31656346    Free PMC article.
Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "Midsummer Night's Dream" or "Much Ado About Nothing"?
Alessandro Antonelli, Carlotta Palumbo, Alfredo Berruti.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656809    Free PMC article.
When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?
Ángel Montero, Raquel Ciérvide, Philip Poortmans.
Curr Oncol Rep, 2019 Oct 31; 21(12). PMID: 31664533
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Jessa Gilda P Pandy, Joanmarie C Balolong-Garcia, Mel Valerie B Cruz-Ordinario, Frances Victoria F Que.
BMC Cancer, 2019 Nov 11; 19(1). PMID: 31703646    Free PMC article.
Systematic Review.
Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer.
Julie L Koenig, Margaret M Kozak, +4 authors, Erqi Pollom.
Cureus, 2019 Nov 15; 11(9). PMID: 31723509    Free PMC article.
Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer.
Xudong Zhu, Jinqi Xue, +7 authors, Yixiao Zhang.
J Cancer, 2019 Nov 19; 10(23). PMID: 31737103    Free PMC article.
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, +4 authors, Emilio Alba.
Front Oncol, 2019 Nov 19; 9. PMID: 31737566    Free PMC article.
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Andrea Ritter, Marc Hirschfeld, +8 authors, Thalia Erbes.
Int J Oncol, 2019 Dec 04; 56(1). PMID: 31789396    Free PMC article.
Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Sebastien Moliere, Isabelle Oddou, +2 authors, Carole Mathelin.
Sci Rep, 2019 Dec 18; 9(1). PMID: 31844135    Free PMC article.
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).
Emanuela Risi, Chiara Biagioni, +14 authors, Luca Malorni.
Ther Adv Med Oncol, 2019 Dec 20; 11. PMID: 31853266    Free PMC article.
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.
Serena Di Cosimo, Valentina Appierto, +11 authors, Matteo Dugo.
Cancers (Basel), 2019 Nov 14; 11(11). PMID: 31717320    Free PMC article.
NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.
Corrado Tinterri, Giuseppe Canavese, Paolo Bruzzi, Beatrice Dozin.
Contemp Clin Trials Commun, 2019 Dec 25; 17. PMID: 31872159    Free PMC article.
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy.
Xinyan Li, Mozhi Wang, +6 authors, Yingying Xu.
J Breast Cancer, 2020 Jan 04; 22(4). PMID: 31897326    Free PMC article.
Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.
Oluwadamilola M Fayanju, Yi Ren, +7 authors, E Shelley Hwang.
Int J Radiat Oncol Biol Phys, 2019 Nov 05; 106(2). PMID: 31678225    Free PMC article.
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.
Eugeni Lopez-Bonet, Maria Buxó, +24 authors, Javier A Menendez.
J Clin Med, 2019 Dec 15; 8(12). PMID: 31835708    Free PMC article.
Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer.
Xiaojie Lin, Rui Xu, +7 authors, Qianjun Chen.
Ann Transl Med, 2020 Jan 14; 7(22). PMID: 31930071    Free PMC article.
Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy.
Xinguang Wang, Yingjian He, +4 authors, Tao Ouyang.
Breast Care (Basel), 2020 Jan 15; 14(6). PMID: 31933585    Free PMC article.
Identification of lncRNAs via microarray analysis for predicting HER2-negative breast cancer response to neoadjuvant chemotherapy.
Dengjie Ouyang, Juan Su, +9 authors, Wenjun Yi.
Int J Clin Exp Pathol, 2018 May 01; 11(5). PMID: 31938376    Free PMC article.
Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
Juan Wu, Rong Kong, +3 authors, Lingquan Kong.
Chin J Cancer Res, 2020 Jan 18; 31(6). PMID: 31949390    Free PMC article.
Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.
Sameer Batoo, Soley Bayraktar, +3 authors, Stefan Glück.
J Carcinog, 2020 Jan 18; 18. PMID: 31949426    Free PMC article.
The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Xinfeng Zhang, Dandan Wang, +6 authors, Feng Jin.
Quant Imaging Med Surg, 2020 Jan 21; 10(1). PMID: 31956542    Free PMC article.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Fara Brasó-Maristany, Gaia Griguolo, +25 authors, Aleix Prat.
Nat Commun, 2020 Jan 22; 11(1). PMID: 31959756    Free PMC article.
Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort.
Sandra Esperanza Díaz-Casas, Jorge Alberto Castilla-Tarra, +10 authors, Juan Carlos Vergel-Martinez.
Oncologist, 2019 Jul 28; 24(12). PMID: 31346133    Free PMC article.
[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer.
Elodie Jouberton, Sébastien Schmitt, +7 authors, Florent Cachin.
EJNMMI Res, 2020 Jan 08; 10(1). PMID: 31907640    Free PMC article.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Takayuki Ueno, Norikazu Masuda, +10 authors, Masakazu Toi.
Jpn J Clin Oncol, 2019 Dec 11; 50(1). PMID: 31821506    Free PMC article.
Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
Nathalie LeVasseur, J Sun, +4 authors, S Chia.
J Cancer Res Clin Oncol, 2019 Nov 20; 146(2). PMID: 31741041
Low total pathologic complete response rate to preoperative chemotherapy in patients with invasive lobular carcinomaof the breast.
Parham Khosravi-Shahi, Luis Cabezón-Gutiérrez, Sara Custodio-Cabello.
Contemp Oncol (Pozn), 2020 Jan 30; 23(4). PMID: 31992958    Free PMC article.
Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies.
Danielle E Desa, Monisha Bhanote, +7 authors, Edward B Brown.
J Biomed Opt, 2019 Aug 29; 24(8). PMID: 31456385    Free PMC article.
Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and after Neoadjuvant Chemotherapy in Breast Cancer
Prihantono Prihantono, Andi Nilawati Usman, +2 authors, Andi Asadul Islam.
Asian Pac J Cancer Prev, 2019 Apr 30; 20(4). PMID: 31030473    Free PMC article.
Imaging breast cancer using hyperpolarized carbon-13 MRI.
Ferdia A Gallagher, Ramona Woitek, +41 authors, Kevin M Brindle.
Proc Natl Acad Sci U S A, 2020 Jan 23; 117(4). PMID: 31964840    Free PMC article.
A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.
Maxine Umeh-Garcia, Catalina Simion, +5 authors, Colleen Sweeney.
Cancer Res, 2019 Nov 07; 80(3). PMID: 31694904    Free PMC article.
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer.
Lucian Pop, Ioan Dumitru Suciu, +2 authors, Oana Daniela Toader.
J Med Life, 2020 Feb 07; 12(4). PMID: 32025249    Free PMC article.
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Mehra Golshan, Sibylle Loibl, +12 authors, Michael Untch.
JAMA Surg, 2020 Jan 09; 155(3). PMID: 31913413    Free PMC article.
Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes.
Amy C Moreno, Yan Heather Lin, +3 authors, Simona F Shaitelman.
J Cancer, 2020 Feb 13; 11(6). PMID: 32047541    Free PMC article.
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
Cansu Karakas, Ashleigh M Francis, +10 authors, Kelly K Hunt.
Ann Surg, 2019 Aug 23;. PMID: 31436549    Free PMC article.
Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Vanessa Petry, Renata Colombo Bonadio, +6 authors, Maria Del Pilar Estevez-Diz.
Fam Cancer, 2019 Nov 22; 19(1). PMID: 31748977
Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Ginés Luengo-Gil, Elena García-Martínez, +7 authors, Francisco Ayala de la Peña.
Cell Oncol (Dordr), 2019 May 23; 42(5). PMID: 31115881
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Nusayba A Bagegni, Yu Tao, Foluso O Ademuyiwa.
PLoS One, 2019 Sep 20; 14(9). PMID: 31536530    Free PMC article.
Biosimilar Trastuzumab in Clinical Trials: Differences or Not?
Marc Thill.
Breast Care (Basel), 2019 Apr 26; 14(1). PMID: 31019438    Free PMC article.
Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles.
Ines Stevic, Gustav Buescher, Franz Lennard Ricklefs.
Cells, 2020 Jan 16; 9(1). PMID: 31935901    Free PMC article.
Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
Ziping Wu, Lei Zhang, +7 authors, Jinsong Lu.
Cancer Biol Ther, 2019 Mar 15; 20(6). PMID: 30866717    Free PMC article.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Everardo D Saad, Pierre Squifflet, +9 authors, Marc Buyse.
Lancet Oncol, 2019 Feb 03; 20(3). PMID: 30709633    Free PMC article.
Systematic Review.
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
Liese Barbier, Paul Declerck, +3 authors, Isabelle Huys.
Br J Cancer, 2019 Jul 02; 121(3). PMID: 31257362    Free PMC article.
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Rana R McKay, Huihui Ye, +16 authors, Mary-Ellen Taplin.
J Clin Oncol, 2019 Feb 28; 37(11). PMID: 30811282    Free PMC article.
The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis.
Qingqing Cheng, Jiaxi Huang, +4 authors, Liangping Luo.
Front Oncol, 2020 Mar 03; 10. PMID: 32117747    Free PMC article.
Systematic Review.
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Sasagu Kurozumi, Kenichi Inoue, +5 authors, Ken Shirabe.
Sci Rep, 2019 Feb 09; 9(1). PMID: 30733496    Free PMC article.
An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
Vera E van der Noord, Ronan P McLaughlin, +4 authors, Bob van de Water.
Sci Rep, 2019 Sep 19; 9(1). PMID: 31527768    Free PMC article.
Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
Yu-Hong Qu, Hai-Tao Zhu, +3 authors, Ying-Shi Sun.
Thorac Cancer, 2020 Jan 17; 11(3). PMID: 31944571    Free PMC article.
Checkpoint blockade in the treatment of breast cancer: current status and future directions.
Lironne Wein, Stephen J Luen, +2 authors, Sherene Loi.
Br J Cancer, 2018 May 29; 119(1). PMID: 29808015    Free PMC article.
Can we establish a hierarchy among trastuzumab biosimilar candidates?
Xavier Pivot, Thierry Petit.
Br J Cancer, 2018 Jul 14; 119(3). PMID: 30002436    Free PMC article.
Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer.
Chuqian Lei, Ciqiu Yang, +11 authors, Kun Wang.
J Breast Cancer, 2020 Mar 07; 23(1). PMID: 32140269    Free PMC article.
Assessment of the Prognostic Staging System of American Joint Committee on Cancer 8th Edition for Breast Cancer: Comparisons with the Conventional Anatomic Staging System.
Eun Jin Kim, Hyung Seok Park, +3 authors, Byeong-Woo Park.
J Breast Cancer, 2020 Mar 07; 23(1). PMID: 32140270    Free PMC article.
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Oluwadamilola M Fayanju, Yi Ren, +8 authors, E Shelley Hwang.
Ann Surg, 2018 Jul 27; 268(4). PMID: 30048319    Free PMC article.
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Aman U Buzdar, Vera J Suman, +6 authors, Kelly K Hunt.
JAMA Oncol, 2018 Sep 08; 5(1). PMID: 30193295    Free PMC article.
Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual.
Jennifer K Plichta, Yi Ren, +5 authors, E Shelley Hwang.
Ann Surg, 2018 Oct 13; 271(1). PMID: 30312199    Free PMC article.
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Amirhessam Tahmassebi, Georg J Wengert, +10 authors, Katja Pinker.
Invest Radiol, 2018 Oct 26; 54(2). PMID: 30358693    Free PMC article.
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui.
Target Oncol, 2018 Nov 09; 13(6). PMID: 30406444    Free PMC article.
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
Diana P Saraiva, António Jacinto, +2 authors, M Guadalupe Cabral.
Front Immunol, 2018 Dec 18; 9. PMID: 30555458    Free PMC article.
Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics.
Tithi Biswas, Charulata Jindal, Timothy L Fitzgerald, Jimmy T Efird.
Int J Environ Res Public Health, 2019 Jan 10; 16(1). PMID: 30621221    Free PMC article.
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Simon Peter Gampenrieder, Andreas Peer, +14 authors, Richard Greil.
Breast Cancer Res, 2019 Feb 02; 21(1). PMID: 30704493    Free PMC article.
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
Ramon Colomer, Cristina Saura, +7 authors, Ana Lluch.
Oncologist, 2019 Feb 03; 24(5). PMID: 30710068    Free PMC article.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Ingrid A Mayer, Aleix Prat, +20 authors, Carlos L Arteaga.
Clin Cancer Res, 2019 Feb 07; 25(10). PMID: 30723140    Free PMC article.
MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer.
Raúl García-Vázquez, Laurence A Marchat, +10 authors, César López-Camarillo.
Technol Cancer Res Treat, 2019 Feb 14; 18. PMID: 30755102    Free PMC article.
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Caitlin Murphy, Andrea Muscat, +10 authors, Mustafa Khasraw.
PLoS One, 2019 Feb 15; 14(2). PMID: 30763338    Free PMC article.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
V Guarneri, M V Dieci, +15 authors, P F Conte.
Ann Oncol, 2019 Feb 20; 30(6). PMID: 30778520    Free PMC article.
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
Wei Cao, Jieqing Li, +2 authors, Yong Wu.
Breast Cancer Res, 2019 Feb 23; 21(1). PMID: 30791936    Free PMC article.
Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
Hanna Piotrzkowska-Wróblewska, Katarzyna Dobruch-Sobczak, +4 authors, Jerzy Litniewski.
PLoS One, 2019 Mar 15; 14(3). PMID: 30870478    Free PMC article.
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.
Gloria V Echeverria, Zhongqi Ge, +27 authors, Helen Piwnica-Worms.
Sci Transl Med, 2019 Apr 19; 11(488). PMID: 30996079    Free PMC article.
Highly Cited.
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
Christian Jackisch, Daniil Stroyakovskiy, +7 authors, Roberto Hegg.
JAMA Oncol, 2019 Apr 19; 5(5). PMID: 30998824    Free PMC article.
Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.
Bruce G Haffty, Linda M McCall, +3 authors, Judy C Boughey.
Int J Radiat Oncol Biol Phys, 2019 May 16; 105(1). PMID: 31085287    Free PMC article.
Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning.
Alberto Bouzón, Ángela Iglesias, +3 authors, Joaquín Mosquera.
Radiol Oncol, 2019 May 20; 53(2). PMID: 31104001    Free PMC article.
Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
Sasagu Kurozumi, Yuri Yamaguchi, +6 authors, Kenichi Inoue.
PLoS One, 2019 May 22; 14(5). PMID: 31112577    Free PMC article.
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Natalie W Harper, Kurt B Hodges, +4 authors, Edward H Romond.
Clin Breast Cancer, 2019 Jun 19; 19(4). PMID: 31208874    Free PMC article.
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Elisa Napolitano Ferreira, Rafael Canfield Brianese, +5 authors, Dirce Maria Carraro.
Transl Oncol, 2019 Aug 17; 12(11). PMID: 31419696    Free PMC article.
Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.
F R Saenz, V Ory, +5 authors, A T Riegel.
Neoplasia, 2019 Aug 23; 21(10). PMID: 31437536    Free PMC article.
Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis.
Yunhai Li, Dejuan Yang, +4 authors, Guosheng Ren.
Aging (Albany NY), 2019 Aug 26; 11(16). PMID: 31446432    Free PMC article.
Circulating tumor cells detection in tumor draining vein of breast cancer patients.
Masaya Hattori, Hayao Nakanishi, +9 authors, Hiroji Iwata.
Sci Rep, 2019 Dec 05; 9(1). PMID: 31796846    Free PMC article.
The evolving role of pathologic complete response in breast cancer.
Nisha Hariharan, T Subramanyeshwar Rao.
South Asian J Cancer, 2019 Dec 07; 8(4). PMID: 31807476    Free PMC article.
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
Ian A MacNeil, David J Burns, +7 authors, Lance G Laing.
J Cancer Res Clin Oncol, 2020 Feb 10; 146(3). PMID: 32036454    Free PMC article.
Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer.
Xenia Elena Bacinschi, Rodica Maricela Anghel, +3 authors, Silvia Mihaela Ilie.
Cancer Manag Res, 2020 Mar 13; 12. PMID: 32161494    Free PMC article.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, +41 authors, Laura J Esserman.
JAMA Oncol, 2020 Feb 14; 6(5). PMID: 32053137    Free PMC article.
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
Serena Di Cosimo, Nicla La Verde, +16 authors, Filippo de Braud.
PLoS One, 2019 Aug 08; 14(8). PMID: 31390375    Free PMC article.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Florence Lerebours, Marina Pulido, +17 authors, Nathalie Quenel-Tueux.
Br J Cancer, 2020 Feb 01; 122(6). PMID: 32001832    Free PMC article.
Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
Daniel S O'Neil, Sarah Nietz, +9 authors, Herbert Cubasch.
Oncologist, 2018 Dec 07; 24(7). PMID: 30518615    Free PMC article.
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line.
Lilla Hámori, Gyöngyi Kudlik, +9 authors, Gergely Szakács.
Int J Mol Sci, 2020 Feb 15; 21(4). PMID: 32053991    Free PMC article.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Serena Di Cosimo, Valentina Appierto, +19 authors, Maria Grazia Daidone.
Int J Mol Sci, 2020 Feb 23; 21(4). PMID: 32085669    Free PMC article.
The Safety and Efficacy of Intra-Arterial versus Intravenous Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer: A Meta-Analysis.
Cheng Liu, Ran Cui, +3 authors, Zhenyu Zhang.
Evid Based Complement Alternat Med, 2020 Mar 19; 2020. PMID: 32184892    Free PMC article.
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Jodi A Kagihara, Michelle Andress, Jennifer R Diamond.
Expert Rev Precis Med Drug Dev, 2020 Mar 20; 5(2). PMID: 32190733    Free PMC article.
Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Yu-Ge Bai, Guo-Xuan Gao, +4 authors, Ling Xu.
Chin Med J (Engl), 2020 Feb 12; 133(5). PMID: 32044815    Free PMC article.
Neoadjuvant radiotherapy in the approach of locally advanced breast cancer.
Cláudia Sousa, Mafalda Cruz, +11 authors, Paula Alves.
ESMO Open, 2020 Mar 11; 4(Suppl 2). PMID: 32152044    Free PMC article.
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.
Daniel Eiger, Mariana Brandão, Evandro de Azambuja.
ESMO Open, 2020 Mar 20; 5(2). PMID: 32188717    Free PMC article.
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Nicci Owusu-Brackett, Ming Zhao, +5 authors, Funda Meric-Bernstam.
Oncotarget, 2020 Mar 28; 11(11). PMID: 32215185    Free PMC article.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Hiroshi Ishiguro, Norikazu Masuda, +16 authors, Masakazu Toi.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170634    Free PMC article.
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
J M Simons, L B Koppert, +5 authors, M L Smidt.
Breast Cancer Res Treat, 2020 Mar 18; 180(3). PMID: 32180074    Free PMC article.
The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
Yuko Nakazawa, Seshiru Nakazawa, +7 authors, Ken Shirabe.
Oncol Lett, 2020 Mar 29; 19(4). PMID: 32218821    Free PMC article.
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Takuro Yamamoto, Noriko Kanaya, George Somlo, Shiuan Chen.
Breast Cancer Res Treat, 2019 Jan 05; 174(3). PMID: 30607633    Free PMC article.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
A Jo Chien, Debasish Tripathy, +47 authors, I-SPY 2 Consortium.
J Clin Oncol, 2020 Feb 08; 38(10). PMID: 32031889    Free PMC article.
Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
Justin Stebbing, Paul N Mainwaring, +4 authors, Hope S Rugo.
J Clin Oncol, 2020 Feb 15; 38(10). PMID: 32058846    Free PMC article.
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.
Mircea Dediu, Christoph Zielinski.
Breast Care (Basel), 2020 Apr 02; 15(1). PMID: 32231500    Free PMC article.
Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620.
Michael Untch, Sibylle Loibl, Peter A Fasching.
Breast Care (Basel), 2020 Apr 02; 15(1). PMID: 32231504    Free PMC article.
Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.
Maren Marie Sjaastad Andreassen, Pål Erik Goa, +7 authors, Neil Peter Jerome.
MAGMA, 2019 Sep 29; 33(2). PMID: 31562584    Free PMC article.
Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
Fuyuhiko Motoi, Michiaki Unno.
Ann Gastroenterol Surg, 2020 Apr 08; 4(2). PMID: 32258974    Free PMC article.
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Bruna Cerbelli, Andrea Botticelli, +11 authors, Giulia d'Amati.
Virchows Arch, 2019 Dec 20; 476(4). PMID: 31853625
360 Health Analysis (H360) - A Proposal for an Integrated Vision of Breast Cancer in Portugal.
Sara Coelho, Inês Brandão Rego, +5 authors, Luís Costa.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285029    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Libo Yang, Feng Ye, +16 authors, Hong Bu.
Cancer Sci, 2019 Feb 19; 110(4). PMID: 30776175    Free PMC article.
Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T.
Erwin Krikken, Wybe J M van der Kemp, +5 authors, Jannie P Wijnen.
NMR Biomed, 2019 Mar 30; 32(6). PMID: 30924571    Free PMC article.
BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
Yoshimasa Kosaka, Yutaka Yamamoto, +6 authors, Sadako Akashi-Tanaka.
Diagnostics (Basel), 2020 Feb 27; 10(2). PMID: 32098267    Free PMC article.
Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
Siyu Wu, Yujie Wang, +8 authors, Guangyu Liu.
Oncologist, 2020 Apr 17; 25(4). PMID: 32297448    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Triple-negative breast cancer: recent treatment advances.
Alice R T Bergin, Sherene Loi.
F1000Res, 2019 Aug 27; 8. PMID: 31448088    Free PMC article.
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Meghan J Bloom, Angela M Jarrett, +4 authors, Anna G Sorace.
BMC Cancer, 2020 Apr 30; 20(1). PMID: 32345237    Free PMC article.
Role of 18F-Flurodeoxyglucose Positron-Emission Tomography/Computed Tomography in the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Triple-Negative Breast Cancer.
Bina Basnet, Pankaj Goyal, +9 authors, Dinesh Chandra Doval.
Indian J Nucl Med, 2020 May 01; 35(2). PMID: 32351263    Free PMC article.
Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer.
Kai Zhang, Jiawei Li, Qian Zhu, Cai Chang.
Cancer Manag Res, 2020 May 06; 12. PMID: 32368138    Free PMC article.
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.
Lidija Antunovic, Rita De Sanctis, +8 authors, Martina Sollini.
Eur J Nucl Med Mol Imaging, 2019 Mar 28; 46(7). PMID: 30915523
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
Bishal Gyawali, Spencer P Hey, Aaron S Kesselheim.
EClinicalMedicine, 2020 May 10; 21. PMID: 32382717    Free PMC article.
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
Nan Wang, Kun Li, +10 authors, Huiping Li.
Chin J Cancer Res, 2020 May 16; 32(2). PMID: 32410793    Free PMC article.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Francesco Schettini, Tomás Pascual, +25 authors, Aleix Prat.
Cancer Treat Rev, 2020 Jan 31; 84. PMID: 32000054    Free PMC article.
Systematic Review.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial.
Laura Pizzuti, Eriseld Krasniqi, +17 authors, Patrizia Vici.
Cancers (Basel), 2020 Apr 05; 12(4). PMID: 32244657    Free PMC article.
The Landscape of Targeted Therapies in TNBC.
Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli.
Cancers (Basel), 2020 Apr 12; 12(4). PMID: 32276534    Free PMC article.
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review.
Iléana Corbeau, William Jacot, Séverine Guiu.
Cancers (Basel), 2020 Apr 17; 12(4). PMID: 32295078    Free PMC article.
The Application of Radiomics in Breast MRI: A Review.
Dong-Man Ye, Hao-Tian Wang, Tao Yu.
Technol Cancer Res Treat, 2020 Apr 30; 19. PMID: 32347167    Free PMC article.
Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset.
Richard Ha, Christine Chin, +7 authors, Sachin Jambawalikar.
J Digit Imaging, 2018 Oct 27; 32(5). PMID: 30361936    Free PMC article.
Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes.
Shiwei Liu, Exian Mou, +8 authors, Jia Xu.
Cancer Manag Res, 2020 May 23; 12. PMID: 32440212    Free PMC article.
Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
Bernhard Tribukait.
BMC Cancer, 2020 May 20; 20(1). PMID: 32423477    Free PMC article.
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
Jieqiang Zhu, Levan Muskhelishvili, +2 authors, Minjun Chen.
Sci Rep, 2020 May 20; 10(1). PMID: 32424219    Free PMC article.
Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.
Joseph Lin, Kuo-Juei Lin, +3 authors, Dar-Ren Chen.
BMC Cancer, 2020 May 22; 20(1). PMID: 32434493    Free PMC article.
Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
Mengmeng Zhang, Ling Li, +5 authors, Haisong Yang.
Biomed Res Int, 2020 May 29; 2020. PMID: 32461977    Free PMC article.
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Hee Jeong Kim, Woo Chul Noh, +7 authors, Sei Hyun Ahn.
Breast Cancer Res, 2020 May 29; 22(1). PMID: 32460816    Free PMC article.
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy.
Claudia Omarini, Stefania Bettelli, +7 authors, Federico Piacentini.
Transl Oncol, 2020 Jun 03; 13(9). PMID: 32485588    Free PMC article.
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
Yuqin Ding, Kaijing Ding, +3 authors, Xiaowen Ding.
PLoS One, 2020 May 30; 15(5). PMID: 32470093    Free PMC article.
Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis.
Julie Labrosse, Marie Osdoit, +4 authors, Enora Laas.
PLoS One, 2020 Jun 06; 15(6). PMID: 32502222    Free PMC article.
Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.
Melissa Davis, Rachel Martini, +15 authors, Clayton Yates.
Cancers (Basel), 2020 May 18; 12(5). PMID: 32414099    Free PMC article.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Giacomo Barchiesi, Marco Mazzotta, +14 authors, Patrizia Vici.
Int J Mol Sci, 2020 May 21; 21(10). PMID: 32429381    Free PMC article.
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Laura M Spring, Geoffrey Fell, +10 authors, Aditya Bardia.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046998    Free PMC article.
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Natsuko Onishi, Wen Li, +9 authors, Nola M Hylton.
Tomography, 2020 Jun 18; 6(2). PMID: 32548283    Free PMC article.
Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.
Jennifer G Whisenant, Jason M Williams, +6 authors, Thomas E Yankeelov.
Tomography, 2020 Jun 18; 6(2). PMID: 32548293    Free PMC article.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
PierFranco Conte, Andreas Schneeweiss, +18 authors, Charles E Geyer.
Cancer, 2020 Apr 15; 126(13). PMID: 32286687    Free PMC article.
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Anne-Sophie Hamy, Lauren Darrigues, +13 authors, Fabien Reyal.
PLoS One, 2020 Jun 25; 15(6). PMID: 32579551    Free PMC article.
Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer.
Koji Takada, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
BMC Cancer, 2020 Jun 28; 20(1). PMID: 32590956    Free PMC article.
Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Jean Schneider, Hyouk Jin Lee, +6 authors, Hongki Gwak.
J Breast Cancer, 2020 Jul 01; 23(3). PMID: 32595988    Free PMC article.
PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Jessica H Byerly, Elisa R Port, Hanna Y Irie.
Breast Cancer Res, 2020 Jul 01; 22(1). PMID: 32600444    Free PMC article.
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Thilde Terkelsen, Francesco Russo, +5 authors, Elena Papaleo.
Breast Cancer Res, 2020 Jul 02; 22(1). PMID: 32605588    Free PMC article.
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ella F Jones, Kimberly M Ray, +7 authors, Nola M Hylton.
Clin Breast Cancer, 2017 Jan 24; 17(3). PMID: 28110902    Free PMC article.
Modern surgical treatment of breast cancer.
M Riis.
Ann Med Surg (Lond), 2020 Jul 09; 56. PMID: 32637082    Free PMC article.
Imaging in Locoregional Management of Breast Cancer.
Christiane K Kuhl, Constance Lehman, Isabelle Bedrosian.
J Clin Oncol, 2020 May 23; 38(20). PMID: 32442068    Free PMC article.
Locoregional Management After Neoadjuvant Chemotherapy.
Monica Morrow, Atif J Khan.
J Clin Oncol, 2020 May 23; 38(20). PMID: 32442069    Free PMC article.
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca Parisi, Maria Grazia Razeti, +7 authors, Matteo Lambertini.
Clin Med Insights Oncol, 2020 Jul 11; 14. PMID: 32647477    Free PMC article.
Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR.
Ramesh Omranipour, Roghiyeh Jalili, +3 authors, Bita Eslami.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656523    Free PMC article.
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model.
F Andreata, A Bonizzi, +17 authors, S Mazzucchelli.
Sci Rep, 2020 Jul 12; 10(1). PMID: 32651443    Free PMC article.
A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
Katerina D Fagan-Solis, Dennis A Simpson, +10 authors, Gaorav P Gupta.
Cell Rep, 2020 Feb 06; 30(5). PMID: 32023457    Free PMC article.
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Jin Sun Lee, Susan E Yost, Yuan Yuan.
Cancers (Basel), 2020 Jun 04; 12(6). PMID: 32486021    Free PMC article.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Essia Mezni, Cécile Vicier, +3 authors, Anthony Gonçalves.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545895    Free PMC article.
Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?
D Le, M Eslami, +3 authors, C Simmons.
Curr Oncol, 2020 Jul 17; 27(3). PMID: 32669932    Free PMC article.
Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.
Z Sun, A Prat, +2 authors, C M Perou.
Ann Oncol, 2014 Oct 31; 26(1). PMID: 25355719    Free PMC article.
The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis.
Yan Li, Yidong Zhou, +4 authors, Qiang Sun.
Front Oncol, 2020 Jul 18; 10. PMID: 32676452    Free PMC article.
Systematic Review.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Ella F Jones, Deep K Hathi, +6 authors, Nola M Hylton.
Cancers (Basel), 2020 Jun 13; 12(6). PMID: 32527022    Free PMC article.
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
I-SPY2 Trial Consortium, Douglas Yee, +77 authors, Donald A Berry.
JAMA Oncol, 2020 Jul 24; 6(9). PMID: 32701140    Free PMC article.
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).
Kimberly S Corbin, William G Breen, Jonathan B Strauss.
Clin Transl Radiat Oncol, 2020 Jul 28; 24. PMID: 32715108    Free PMC article.
Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy.
Roberto Lo Gullo, Sarah Eskreis-Winkler, Elizabeth A Morris, Katja Pinker.
Breast, 2019 Dec 02; 49. PMID: 31786416    Free PMC article.
Expression of tumor-associated antigens in breast cancer subtypes.
Giuseppe Curigliano, Vincenzo Bagnardi, +7 authors, Giuseppe Viale.
Breast, 2019 Dec 24; 49. PMID: 31869767    Free PMC article.
Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance.
Dong Won Baek, Ji-Young Park, Soo Jung Lee, Yee Soo Chae.
Yeungnam Univ J Med, 2020 Jan 22; 37(3). PMID: 31962039    Free PMC article.
Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.
Ida Skarping, Daniel Förnvik, +4 authors, Signe Borgquist.
Breast, 2020 Jun 21; 53. PMID: 32563178    Free PMC article.
Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer.
Alexey Surov, Andreas Wienke, Hans Jonas Meyer.
Breast, 2020 Jul 12; 53. PMID: 32652460    Free PMC article.
Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
Koichi Kubouchi, Kyosuke Shimada, Takamichi Yokoe, Yutaka Tsutsumi.
Technol Cancer Res Treat, 2020 Jul 18; 19. PMID: 32677589    Free PMC article.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Sanxing Guo, Sibylle Loibl, +3 authors, Carsten Denkert.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019278    Free PMC article.
Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters.
Harry D Bear, Kandace P McGuire.
Ann Surg Oncol, 2019 Apr 26; 26(8). PMID: 31020504    Free PMC article.
The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
Nina Tamirisa, Hannah V Williamson, +7 authors, Oluwadamilola M Fayanju.
J Surg Oncol, 2019 May 08; 120(2). PMID: 31062375    Free PMC article.
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Melissa Krystel-Whittemore, Jin Xu, +8 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2019 May 31; 177(1). PMID: 31144151    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Nina Ditsch, Michael Untch, +42 authors, Achim Wöckel.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558897    Free PMC article.
Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics.
Doris Leithner, Marius E Mayerhoefer, +4 authors, Katja Pinker.
J Clin Med, 2020 Jun 18; 9(6). PMID: 32545851    Free PMC article.
Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency.
Gianluca Vanni, Marco Pellicciaro, +11 authors, Oreste Claudio Buonomo.
Breast Cancer, 2020 Aug 01; 28(1). PMID: 32734327    Free PMC article.
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Kai Li, Ning Liao, +18 authors, Ning Liao.
Breast Cancer Res Treat, 2020 Jul 09; 183(2). PMID: 32638235    Free PMC article.
Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results.
Karina Quiaoit, Daniel DiCenzo, +19 authors, Gregory J Czarnota.
PLoS One, 2020 Jul 28; 15(7). PMID: 32716959    Free PMC article.
A Six-Epithelial-Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer.
Li Yuan Wei, Xiao Jun Zhang, +4 authors, Jin Nan Gao.
Onco Targets Ther, 2020 Aug 06; 13. PMID: 32753890    Free PMC article.
Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.
Soong June Bae, Yoon Jin Cha, +10 authors, Joon Jeong.
Sci Rep, 2020 Aug 06; 10(1). PMID: 32753659    Free PMC article.
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Ann-Kathrin Bittner, Corinna Keup, +3 authors, Sabine Kasimir-Bauer.
J Cell Mol Med, 2020 Jun 20; 24(15). PMID: 32558176    Free PMC article.
Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis.
Ekaterina Ivanova, Ambber Ward, Adrian P Wiegmans, Derek John Richard.
Front Mol Biosci, 2020 Aug 09; 7. PMID: 32766277    Free PMC article.
Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
Mercedes Herrera Juarez, Pablo Tolosa Ortega, Ana Sanchez de Torre, Eva Ciruelos Gil.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774214    Free PMC article.
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
Jenny Furlanetto, Sibylle Loibl.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774215    Free PMC article.
Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].
Mircea Dediu, Christoph Zielinski.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774227    Free PMC article.
Outcome of post-mastectomy radiotherapy after primary systemic treatment in patients with different clinical tumor and nodal stages of breast cancer: a cohort study.
Jia-Qiang Zhang, Chang-Yun Lu, +2 authors, Szu-Yuan Wu.
Am J Cancer Res, 2020 Aug 11; 10(7). PMID: 32775010    Free PMC article.
Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Andrew McGuire, Maire-Caitlin Casey, +11 authors, Michael J Kerin.
Cancers (Basel), 2020 Jul 11; 12(7). PMID: 32645898    Free PMC article.
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
Silvia González-Martínez, Belén Pérez-Mies, +4 authors, José Palacios.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650408    Free PMC article.
MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
Stephen F Sener, Rachel E Sargent, +7 authors, Julie E Lang.
J Surg Oncol, 2019 Aug 11; 120(6). PMID: 31400007    Free PMC article.
How shall we treat locally advanced triple negative breast cancer?
Paulo Luz, David Dias, +2 authors, Beatriz Gosalbez.
F1000Res, 2020 Aug 21; 8. PMID: 32802311    Free PMC article.
Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ramona Woitek, Mary A McLean, +27 authors, Ferdia A Gallagher.
Radiol Imaging Cancer, 2020 Aug 18; 2(4). PMID: 32803167    Free PMC article.
Management of early breast cancer during the COVID-19 pandemic in Brazil.
Francisco Pimentel Cavalcante, Guilherme Garcia Novita, +4 authors, Ruffo Freitas Junior.
Breast Cancer Res Treat, 2020 Aug 18; 184(2). PMID: 32803637    Free PMC article.
Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
Yong Li, Xiaoju Lu, Qimou Lin, Weiwen Li.
J Int Med Res, 2020 Aug 09; 48(8). PMID: 32762463    Free PMC article.
Early stage triple negative breast cancer: Management and future directions.
Lubna N Chaudhary.
Semin Oncol, 2020 Jun 09; 47(4). PMID: 32507668    Free PMC article.
"To Anticipate": Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers.
Mattia Garutti, Silvia Buriolla, +5 authors, Fabio Puglisi.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32708968    Free PMC article.
Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.
Mari Gasparyan, Miao-Chia Lo, +2 authors, Duxin Sun.
J Biol Chem, 2020 May 30; 295(34). PMID: 32467227    Free PMC article.
Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.
M Patricia George, Mark T Gladwin, Brian B Graham.
Am J Respir Cell Mol Biol, 2020 May 27; 63(3). PMID: 32453969    Free PMC article.
Fasting-mimicking diet plus chemotherapy in breast cancer treatment.
Claudio Vernieri, Francesca Ligorio, +2 authors, Filippo de Braud.
Nat Commun, 2020 Aug 28; 11(1). PMID: 32848145    Free PMC article.
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors.
María Rosario Chica-Parrado, Ana Godoy-Ortiz, +3 authors, Emilio Alba.
Cancers (Basel), 2020 Jul 28; 12(8). PMID: 32708049    Free PMC article.
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.
Aena Patel, Nisha Unni, Yan Peng.
Cancers (Basel), 2020 Aug 01; 12(8). PMID: 32731409    Free PMC article.
Management of the Axilla after Neoadjuvant Systemic Therapy.
Trista J Stankowski-Drengler, Heather B Neuman.
Curr Treat Options Oncol, 2020 May 29; 21(7). PMID: 32462230    Free PMC article.
Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer.
Takashi Takeshita, Li Yan, +5 authors, Kazuaki Takabe.
Am J Cancer Res, 2020 Sep 10; 10(8). PMID: 32905537    Free PMC article.
Breast Cancer Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy by Receptor Subtype: A Scoping Review.
Trista J Stankowski-Drengler, Devon Livingston-Rosanoff, +3 authors, Heather B Neuman.
J Surg Res, 2020 May 19; 254. PMID: 32422430    Free PMC article.
Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
Justin Zonneville, Sean Colligan, +4 authors, Andrei V Bakin.
Int J Cancer, 2020 May 27; 147(8). PMID: 32452014    Free PMC article.
Evaluating the current evidence to support therapeutic mammoplasty or breast-conserving surgery as an alternative to mastectomy in the treatment of multifocal and multicentric breast cancers.
Zoe Ellen Winters, Lorenzo Bernaudo.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687626    Free PMC article.
Bufalin attenuates triple-negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4.
Fei Chen, Li Zhu, +6 authors, Zhe Li.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934738    Free PMC article.
The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer.
Yan Wang, Ziping Wu, +9 authors, Jinsong Lu.
Gland Surg, 2020 Sep 22; 9(4). PMID: 32953602    Free PMC article.
Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.
Jiujun Zhu, Jianbin Li, +8 authors, Zhenzhen Liu.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953792    Free PMC article.
A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.
Yueyao Du, Tingting Yan, +2 authors, Jinsong Lu.
Breast Cancer (Dove Med Press), 2018 Dec 21; 10. PMID: 30568487    Free PMC article.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Brian Godman, Anna Bucsics, +49 authors, Alan Haycox.
Front Public Health, 2018 Dec 21; 6. PMID: 30568938    Free PMC article.
Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.
Mao Shang, Chunxiao Chang, +3 authors, HuiHui Li.
J Cancer, 2018 Dec 28; 9(24). PMID: 30588246    Free PMC article.
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.
Silvia Antolín, Benigno Acea, +7 authors, Lourdes Calvo.
Breast Cancer (Dove Med Press), 2019 Jan 16; 11. PMID: 30643452    Free PMC article.
Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis.
Wenhua Ma, Fugang Zhao, +4 authors, Peng Xie.
Onco Targets Ther, 2019 Jan 19; 12. PMID: 30655674    Free PMC article.
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study.
Kritiya Butthongkomvong, Nilubol Raunroadroong, +4 authors, Stig Larsen.
Breast Cancer (Dove Med Press), 2019 Jan 23; 11. PMID: 30666153    Free PMC article.
HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer.
Mikheil Gogiashvili, Jessica Nowacki, +3 authors, Karolina Edlund.
Metabolites, 2019 Jan 27; 9(2). PMID: 30678289    Free PMC article.
Primary medical therapy and breast conservation treatment: the medical oncology perspective.
Nan Soon Wong.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687629    Free PMC article.
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs.
Oriol Solà-Morales, Timm Volmer, Lorenzo Mantovani.
J Mark Access Health Policy, 2019 Feb 06; 7(1). PMID: 30719243    Free PMC article.
Triple-negative breast cancer: the reality in Chile and in Latin America.
Christian Caglevic, Jaime Anabalón, +6 authors, Mauricio Mahave.
Ecancermedicalscience, 2019 Feb 23; 13. PMID: 30792810    Free PMC article.
Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research.
Cigdem Selli, Andrew H Sims.
Breast Cancer (Auckl), 2019 Mar 01; 13. PMID: 30814840    Free PMC article.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient.
Omar Hamdy.
J Breast Cancer, 2019 Apr 04; 22(1). PMID: 30941242    Free PMC article.
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
Olga Caramelo, Cristina Silva, +2 authors, Teresa Almeida-Santos.
Hered Cancer Clin Pract, 2019 Apr 10; 17. PMID: 30962858    Free PMC article.
Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy.
Ziping Wu, Lei Zhang, +7 authors, Jinsong Lu.
Cancer Cell Int, 2019 Apr 13; 19. PMID: 30976202    Free PMC article.
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.
Elisabet Cuyàs, Maria Buxó, +23 authors, Javier A Menendez.
Front Oncol, 2019 Apr 16; 9. PMID: 30984619    Free PMC article.
Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis.
Di Wu, Tiejun Chen, +5 authors, Fenfang Wu.
J Oncol, 2019 Apr 25; 2019. PMID: 31015833    Free PMC article.
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
Ella F Jones, Kimberly M Ray, +8 authors, Nola M Hylton.
NPJ Breast Cancer, 2019 Apr 25; 5. PMID: 31016232    Free PMC article.
Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.
Renaud Sabatier, Emmanuelle Charafe-Jauffret, +10 authors, Anthony Gonçalves.
J Clin Med, 2019 May 09; 8(5). PMID: 31064127    Free PMC article.
Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
Yushi Ueki, Yuichiro Tada, +3 authors, Yuichiro Sato.
Int Cancer Conf J, 2016 Mar 22; 5(3). PMID: 31149444    Free PMC article.
Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.
Yueyao Du, Liheng Zhou, +3 authors, Jinsong Lu.
Ann Transl Med, 2019 Jun 04; 7(7). PMID: 31157259    Free PMC article.
Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy.
Yi-Wei Tong, Gen Wang, +7 authors, Kun-Wei Shen.
Onco Targets Ther, 2019 Jun 14; 12. PMID: 31190894    Free PMC article.
Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers.
Nilgun Yildirim, Melih Simsek, +2 authors, Salim Basol Tekin.
Eurasian J Med, 2019 Jul 02; 51(2). PMID: 31258356    Free PMC article.
ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
Marco La Ferla, Francesca Lessi, +18 authors, Chiara M Mazzanti.
Front Oncol, 2019 Jul 13; 9. PMID: 31297336    Free PMC article.
Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment.
Vladimir M Perelmuter, Liubov A Tashireva, +4 authors, Nadezhda V Cherdyntseva.
Breast Cancer (Dove Med Press), 2019 Jul 17; 11. PMID: 31308736    Free PMC article.
Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran.
Dena Firouzabadi, Alireza Rezvani, Amirreza Dehghanian, Laleh Mahmoudi.
Cancer Manag Res, 2019 Aug 03; 11. PMID: 31372050    Free PMC article.
Neoadjuvant therapy of locally/regionally advanced melanoma.
Arjun Khunger, Zachary S Buchwald, +3 authors, Ahmad A Tarhini.
Ther Adv Med Oncol, 2019 Aug 09; 11. PMID: 31391869    Free PMC article.
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM).
Maria Vittoria Dieci, Lucia Del Mastro, +14 authors, Stefania Gori.
Cancers (Basel), 2019 Aug 11; 11(8). PMID: 31398896    Free PMC article.
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.
Tarek M A Abdel-Fatah, Reem Ali, +7 authors, Srinivasan Madhusudan.
Cancers (Basel), 2019 Aug 14; 11(8). PMID: 31405143    Free PMC article.
Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy.
Yue Zhao, Xiaolei Wang, +2 authors, Dongwei Zhang.
Cancer Manag Res, 2019 Aug 17; 11. PMID: 31417311    Free PMC article.
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.
Li-Tong Yao, Mo-Zhi Wang, +5 authors, Ying-Ying Xu.
World J Clin Cases, 2019 Aug 20; 7(15). PMID: 31423426    Free PMC article.
Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women.
Sandra Diaz Casas, Eder Lancheros García, +7 authors, Juan C Vergel.
Cureus, 2019 Aug 28; 11(6). PMID: 31453035    Free PMC article.
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra, Giuseppe Curigliano.
NPJ Breast Cancer, 2019 Sep 05; 5. PMID: 31482107    Free PMC article.
Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.
Emily Z Keung, Jeffrey E Gershenwald.
J Natl Cancer Inst, 2020 Feb 16; 112(9). PMID: 32061122    Free PMC article.
Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
José Bines, Isabele A Small, +9 authors, Martin Bonamino.
Oncologist, 2020 Jun 02; 25(9). PMID: 32476183    Free PMC article.
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Federica Miglietta, Maria Vittoria Dieci, +14 authors, Valentina Guarneri.
Oncologist, 2020 Jul 04; 25(9). PMID: 32618068    Free PMC article.
Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.
Carlie K Thompson, Minna K Lee, +2 authors, Maggie L DiNome.
Ann Surg, 2020 Jul 18; 272(2). PMID: 32675509    Free PMC article.
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Luca Cavallone, Adriana Aguilar-Mahecha, +17 authors, Mark Basik.
Sci Rep, 2020 Sep 09; 10(1). PMID: 32895401    Free PMC article.
Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
Ozkan Alan, Tugba Akin Telli, +13 authors, Perran Fulden Yumuk.
World J Surg Oncol, 2020 Sep 11; 18(1). PMID: 32907593    Free PMC article.
Proteomic patterns associated with response to breast cancer neoadjuvant treatment.
Anjana Shenoy, Nishanth Belugali Nataraj, +12 authors, Tamar Geiger.
Mol Syst Biol, 2020 Sep 23; 16(9). PMID: 32960509    Free PMC article.
HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment.
Franziska M Wuerfel, Hanna Huebner, +12 authors, Matthias Ruebner.
Sci Rep, 2020 Sep 27; 10(1). PMID: 32978482    Free PMC article.
Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer.
Shuai Yan, Wenjie Wang, +3 authors, Weiyang Tao.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982426    Free PMC article.
Downregulation of Immortalization-Upregulated Protein Suppresses the Progression of Breast Cancer Cell Lines by Regulating Epithelial-Mesenchymal Transition.
Jialiang Wen, Lizhi Lin, +3 authors, Ouchen Wang.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982454    Free PMC article.
Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1+ CD8+ and CD8+ T cells as predictive of response to neoadjuvant chemotherapy in breast cancer.
Hongling Liang, Hongsheng Li, +17 authors, Yi-Long Wu.
Thorac Cancer, 2020 Sep 08; 11(10). PMID: 32894006    Free PMC article.
Teleoncology: The Youngest Pillar of Oncology.
Puneet Pareek, Jeewan Ram Vishnoi, +2 authors, Sanjeev Misra.
JCO Glob Oncol, 2020 Oct 01; 6. PMID: 32997540    Free PMC article.
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Rubina Manuela Trimboli, Paolo Giorgi Rossi, +4 authors, Francesco Sardanelli.
Insights Imaging, 2020 Sep 26; 11(1). PMID: 32975658    Free PMC article.
Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique.
Mariana Brandão, Assucena Guisseve, +13 authors, Nuno Lunet.
ESMO Open, 2020 Oct 07; 5(5). PMID: 33020218    Free PMC article.
Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort.
Jesse Lopes da Silva, Bruno Henrique Rala de Paula, +2 authors, Andréia Cristina de Melo.
Breast Cancer (Auckl), 2020 Oct 09; 14. PMID: 33029072    Free PMC article.
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.
Sarah Talamantes, Eric Xie, +3 authors, Cesar A Santa-Maria.
Cancer Med, 2020 Aug 07; 9(19). PMID: 32757467    Free PMC article.
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Giacomo Montagna, Varadan Sevilimedu, +3 authors, Melissa L Pilewskie.
Ann Surg Oncol, 2020 Aug 26; 27(12). PMID: 32839900    Free PMC article.
Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy.
Mahmut Büyükşimşek, Ali Oğul, Cem Mirili, Semra Paydaş.
Eur J Breast Health, 2020 Oct 17; 16(4). PMID: 33062961    Free PMC article.
Breast-conserving surgery with or without irradiation in women with invasive ductal carcinoma of the breast receiving preoperative systemic therapy: A cohort study.
Jiaqiang Zhang, Chang-Yun Lu, +2 authors, Szu-Yuan Wu.
Breast, 2020 Oct 14; 54. PMID: 33049657    Free PMC article.
Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Sungchan Gwark, Jisun Kim, +23 authors, Sei Hyun Ahn.
Sci Rep, 2020 Oct 17; 10(1). PMID: 33060768    Free PMC article.
Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Marion M Deken, Marta M Kijanka, +8 authors, Sabrina Oliveira.
J Control Release, 2020 Apr 25; 323. PMID: 32330574    Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials.
Daniele Marinelli, Marco Mazzotta, +14 authors, Patrizia Vici.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899209    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Early Prediction of Tumor Response to Neoadjuvant Chemotherapy and Clinical Outcome in Breast Cancer Using a Novel FDG-PET Parameter for Cancer Stem Cell Metabolism.
Chanwoo Kim, Sang-Ah Han, +2 authors, Deog Yoon Kim.
J Pers Med, 2020 Sep 23; 10(3). PMID: 32957507    Free PMC article.
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC.
Luca Campedel, Paul Blanc-Durand, +15 authors, Sylvie Giacchetti.
Cancers (Basel), 2020 Sep 23; 12(9). PMID: 32957722    Free PMC article.
Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01).
T J Stankowski-Drengler, J R Schumacher, +5 authors, H B Neuman.
Ann Surg Oncol, 2020 Jan 05; 27(3). PMID: 31900808    Free PMC article.
A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer.
Dimitrios Korentzelos, Amanda M Clark, Alan Wells.
Int J Mol Sci, 2020 Oct 08; 21(19). PMID: 33022920    Free PMC article.
Neoadjuvant chemotherapy: practice and thinking for Chinese patients with early breast cancer.
Xue-Fei Wang, Song-Jie Shen, +4 authors, Qiang Sun.
Chin Med J (Engl), 2020 Aug 10; 133(19). PMID: 32769502    Free PMC article.
Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Ileana Corbeau, Simon Thezenas, +3 authors, Severine Guiu.
Cancers (Basel), 2020 Sep 24; 12(9). PMID: 32962003    Free PMC article.
A Pilot Study of the Impact of Microwave Ablation on the Dielectric Properties of Breast Tissue.
Luz Maria Neira, R Owen Mays, +6 authors, Susan C Hagness.
Sensors (Basel), 2020 Oct 11; 20(19). PMID: 33036268    Free PMC article.
Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial.
Takanori Kin, Shoichiro Ohtani, +9 authors, Koichi Hiraki.
World J Oncol, 2020 Oct 30; 11(5). PMID: 33117463    Free PMC article.
Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node-positive breast cancer: How can we select patients?
Marianne van Zeeland, Paulien Westhoff, +5 authors, Hanneke Meijer.
Breast J, 2020 Jun 12; 26(9). PMID: 32524674    Free PMC article.
FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction.
Shuo Liu, Haobin Wang, +7 authors, Shijing Yue.
Cell Death Dis, 2020 Sep 27; 11(9). PMID: 32978372    Free PMC article.
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Xiangmei Zhang, Jingping Li, +4 authors, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145271    Free PMC article.
The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients.
Lu Sun, Wenjin Yin, +2 authors, Jinsong Lu.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154826    Free PMC article.
Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.
Max A A Ragusi, Claudette E Loo, +5 authors, Kenneth G A Gilhuijs.
Eur Radiol, 2020 Jul 22; 30(12). PMID: 32691100    Free PMC article.
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
Sacha J Howell, Faye Coe, +2 authors, Maria Ekholm.
Breast Cancer Res Treat, 2020 Aug 30; 184(2). PMID: 32860550    Free PMC article.
Pathologic response as predictor of recurrence, metastasis, and survival in breast cancer patients receiving neoadjuvant chemotherapy and total mastectomy.
Jiaqiang Zhang, Mingyang Sun, +3 authors, Szu-Yuan Wu.
Am J Cancer Res, 2020 Nov 10; 10(10). PMID: 33163280    Free PMC article.
A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.
Sarah Nietz, Daniel S O'Neil, +13 authors, Herbert Cubasch.
Breast Cancer Res Treat, 2020 Sep 03; 184(3). PMID: 32875480    Free PMC article.
Landmark trials in the medical oncology management of early stage breast cancer.
Whitney Hensing, Cesar A Santa-Maria, Lindsay L Peterson, Jennifer Y Sheng.
Semin Oncol, 2020 Sep 17; 47(5). PMID: 32933761    Free PMC article.
Update Breast Cancer 2020 Part 3 - Early Breast Cancer.
Jens Huober, Andreas Schneeweiss, +16 authors, Achim Wöckel.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173238    Free PMC article.
HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer.
Franziska M Würfel, Ralph M Wirtz, +8 authors, Claudio Zamagni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173240    Free PMC article.
Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Zhen-Yu Li, Zhen Zhang, +2 authors, Sha-Sha Ren.
J Int Med Res, 2020 Oct 27; 48(10). PMID: 33100072    Free PMC article.
Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer.
Ryungsa Kim, Ami Kawai, +10 authors, Koji Arihiro.
Transl Oncol, 2020 Nov 07; 14(1). PMID: 33157515    Free PMC article.
Do all patients with breast cancer benefit from neoadjuvant chemotherapy?
Kyoung Eun Lee.
Korean J Intern Med, 2020 Nov 06; 35(6). PMID: 33147906    Free PMC article.
Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer.
Rajat Bajaj, Rupal Tripathi, +5 authors, Dinesh Chandra Doval.
PLoS One, 2020 Nov 12; 15(11). PMID: 33175907    Free PMC article.
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Bruno Coudert, Jean-Yves Pierga, +17 authors, Laurent Arnould.
EClinicalMedicine, 2020 Nov 19; 28. PMID: 33205032    Free PMC article.
Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
In Hee Lee, Soo Jung Lee, +5 authors, Yee Soo Chae.
BMC Cancer, 2020 Nov 18; 20(1). PMID: 33198673    Free PMC article.
Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).
Shengyu Pu, Ke Wang, +4 authors, Jian Zhang.
BMC Cancer, 2020 Nov 21; 20(1). PMID: 33213397    Free PMC article.
Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
Tobias Berg, Maj-Britt Jensen, +3 authors, Michael Andersson.
Breast, 2020 Nov 14; 54. PMID: 33186804    Free PMC article.
Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer.
Shicong Tang, Ke Wang, +8 authors, Rong Guo.
Gland Surg, 2020 Nov 24; 9(5). PMID: 33224817    Free PMC article.
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A Hurvitz, Jennifer L Caswell-Jin, +22 authors, Dennis J Slamon.
Nat Commun, 2020 Nov 19; 11(1). PMID: 33203854    Free PMC article.
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.
Katherine L Pogue-Geile, Nan Song, +15 authors, E Aubrey Thompson.
JNCI Cancer Spectr, 2020 Nov 27; 4(5). PMID: 33241186    Free PMC article.
The Tumor-Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy.
Hwan-Ho Cho, Minsu Park, +5 authors, Sung Hoon Sim.
Biology (Basel), 2020 Nov 14; 9(11). PMID: 33182628    Free PMC article.
Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Diana Lüftner, Gary H Lyman, +2 authors, Minji Seo.
Target Oncol, 2020 Aug 05; 15(4). PMID: 32748046    Free PMC article.
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Natalia Kunst, Shi-Yi Wang, +4 authors, Lajos Pusztai.
JAMA Netw Open, 2020 Nov 24; 3(11). PMID: 33226431    Free PMC article.
Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Sandy C Lee, Edward Grant, +7 authors, Linda Hovanessian-Larsen.
J Ultrasound Med, 2017 Feb 06; 36(5). PMID: 28150325    Free PMC article.
Neoadjuvant chemoradiation and breast reconstruction: the potential for improved outcomes in the treatment of breast cancer.
Niamh O' Halloran, Terri McVeigh, +3 authors, Michael Kerin.
Ir J Med Sci, 2018 Jun 28; 188(1). PMID: 29948462
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Elizabeth Hope Cain, Ashirbani Saha, +3 authors, Maciej A Mazurowski.
Breast Cancer Res Treat, 2018 Oct 18; 173(2). PMID: 30328048    Free PMC article.
The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy.
Hiromi Koyasu, Satoshi Goshima, +5 authors, Masayuki Matsuo.
Jpn J Radiol, 2018 Nov 06; 37(1). PMID: 30392134
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Elaine M Walsh, Aliaa Shalaby, +6 authors, Grace M Callagy.
Breast Cancer Res Treat, 2018 Nov 30; 174(1). PMID: 30488345    Free PMC article.
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Wânia Cristina da Silva, Vânia Eloisa de Araujo, +8 authors, Eli Iola Gurgel Andrade.
BioDrugs, 2018 Dec 01; 32(6). PMID: 30499082    Free PMC article.
Systematic Review.
A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
David G Hicks, Brandon Buscaglia, +6 authors, Yasushi Nakano.
BMC Cancer, 2018 Dec 20; 18(1). PMID: 30563489    Free PMC article.
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Achim Wöckel, Jasmin Festl, +94 authors, Stephanie Stangl.
Geburtshilfe Frauenheilkd, 2018 Dec 26; 78(11). PMID: 30581198    Free PMC article.
The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis.
Chi Zhang, Ying Guo, +2 authors, Xuening Duan.
Medicine (Baltimore), 2019 Feb 01; 98(5). PMID: 30702584    Free PMC article.
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Xinyi Chen, Yonghai Guo, +7 authors, Yuntao Xie.
J Cancer Res Clin Oncol, 2019 Feb 27; 145(5). PMID: 30806788
Impact of obesity on breast cancer recurrence and minimal residual disease.
Brett L Ecker, Jun Y Lee, +10 authors, Lewis A Chodosh.
Breast Cancer Res, 2019 Mar 15; 21(1). PMID: 30867005    Free PMC article.
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
A F de Groot, E J Blok, +11 authors, J R Kroep.
Breast Cancer Res Treat, 2019 Mar 15; 175(3). PMID: 30868392    Free PMC article.
Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.
Andreas D Hartkopf, Volkmar Müller, +14 authors, Hans Tesch.
Geburtshilfe Frauenheilkd, 2019 Mar 19; 79(3). PMID: 30880824    Free PMC article.
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Hsu-Huan Chou, Wen-Ling Kuo, +10 authors, Shin-Cheh Chen.
Biomed J, 2019 Apr 17; 42(1). PMID: 30987708    Free PMC article.
Robust identification of molecular phenotypes using semi-supervised learning.
Heinrich Roder, Carlos Oliveira, +3 authors, Joanna Roder.
BMC Bioinformatics, 2019 May 30; 20(1). PMID: 31138112    Free PMC article.
Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel.
Hans-Christian Kolberg, Andreas Schneeweiss, +18 authors, Sara Y Brucker.
Geburtshilfe Frauenheilkd, 2019 Jun 01; 79(5). PMID: 31148847    Free PMC article.
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Andreas Schneeweiss, Carsten Denkert, +5 authors, Hans-Joachim Lück.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217629    Free PMC article.
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.
Mariana Brandão, Fabien Reyal, Anne-Sophie Hamy, Martine Piccart-Gebhart.
ESMO Open, 2019 Jun 25; 4(3). PMID: 31231570    Free PMC article.
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
C Elfgen, K Reeve, +5 authors, Z Varga.
J Cancer Res Clin Oncol, 2019 Jul 05; 145(8). PMID: 31270600
Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC).
Alexander Philipovskiy, Javier Corral, +2 authors, Sumit Gaur.
In Vivo, 2019 Jul 08; 33(4). PMID: 31280213    Free PMC article.
Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy.
Stephen L Luen, Roberto Salgado, Sherene Loi.
Oncotarget, 2019 Aug 07; 10(45). PMID: 31384388    Free PMC article.
Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients.
Devon Livingston-Rosanoff, Bret Hanlon, +6 authors, Lee G Wilke.
Breast J, 2019 Sep 13; 26(4). PMID: 31513322    Free PMC article.
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Sandra M Swain, Gong Tang, +10 authors, Norman Wolmark.
Clin Cancer Res, 2020 May 07; 26(16). PMID: 32371537    Free PMC article.
Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007).
Qi Zhou, Hai-Ping Zhang, +5 authors, Chinese Society of Breast Surgery.
Chin Med J (Engl), 2020 Sep 15; 133(21). PMID: 32925286    Free PMC article.
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Yeon Hee Park, Samir Lal, +28 authors, Zhengyan Kan.
Nat Commun, 2020 Dec 04; 11(1). PMID: 33268821    Free PMC article.
Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Suleyman Ozkan Aksoy, Ali İbrahim Sevinc, +6 authors, Büşra Emir.
Medicine (Baltimore), 2020 Dec 09; 99(49). PMID: 33285770    Free PMC article.
Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.
Hans-Christian Kolberg, Thorsten Kühn, +13 authors, Cornelia Kolberg-Liedtke.
Geburtshilfe Frauenheilkd, 2020 Dec 10; 80(12). PMID: 33293731    Free PMC article.
Towards personalized treatment for early stage HER2-positive breast cancer.
Kristina Goutsouliak, Jamunarani Veeraraghavan, +4 authors, Rachel Schiff.
Nat Rev Clin Oncol, 2019 Dec 15; 17(4). PMID: 31836877    Free PMC article.
I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer.
Haiyun Wang, Douglas Yee.
Curr Breast Cancer Rep, 2020 Dec 15; 11(4). PMID: 33312344    Free PMC article.
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.
Claudia De Angelis, Michail Ignatiadis, Martine Piccart-Gebhart.
Ann Transl Med, 2020 Dec 15; 8(21). PMID: 33313083    Free PMC article.
Oncologic Outcomes After Neoadjuvant Chemotherapy and Postmastectomy Breast Reconstruction.
Oluwadamilola M Fayanju, Scott T Hollenbeck, Rachel A Greenup.
JAMA Surg, 2020 Oct 15; 155(12). PMID: 33052373    Free PMC article.
Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Hui Yan, Hui Xiao, +2 authors, Zhenzhen Liu.
Cancer Manag Res, 2020 Dec 18; 12. PMID: 33328766    Free PMC article.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Riccardo Lobefaro, Emma Zattarin, +15 authors, Giuseppe Capri.
Ther Adv Med Oncol, 2020 Dec 19; 12. PMID: 33335565    Free PMC article.
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.
Emma Zattarin, Rita Leporati, +4 authors, Claudio Vernieri.
Cells, 2020 Dec 16; 9(12). PMID: 33316954    Free PMC article.
Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
T Younis, A Lee, +4 authors, G S Jhuti.
Curr Oncol, 2021 Jan 01; 27(6). PMID: 33380873    Free PMC article.
Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
Haiyun Wang, Shijia Zhang, +4 authors, Anne Blaes.
Breast Cancer, 2021 Jan 03; 28(3). PMID: 33387284
Patterns of Regression in Breast Cancer after Primary Systemic Treatment.
Tamás Zombori, Gábor Cserni.
Pathol Oncol Res, 2018 Nov 30; 25(3). PMID: 30484262
Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems.
Max S Mano.
Breast, 2020 Dec 07; 54. PMID: 33279792    Free PMC article.
Neoadjuvant checkpoint blockade for cancer immunotherapy.
Suzanne L Topalian, Janis M Taube, Drew M Pardoll.
Science, 2020 Feb 01; 367(6477). PMID: 32001626    Free PMC article.
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Katherine Sanchez, Isaac Kim, +11 authors, David B Page.
Breast Cancer Res, 2021 Jan 09; 23(1). PMID: 33413574    Free PMC article.
Comparison of Overall Survival Between Invasive Lobular Breast Carcinoma and Invasive Ductal Breast Carcinoma: A Propensity Score Matching Study Based on SEER Database.
Ciqiu Yang, Chuqian Lei, +8 authors, Kun Wang.
Front Oncol, 2021 Jan 09; 10. PMID: 33415073    Free PMC article.
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Dena Firouzabadi, Amirreza Dehghanian, +2 authors, Abdolrasoul Talei.
BMC Cancer, 2021 Jan 13; 21(1). PMID: 33430808    Free PMC article.
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Kimberly H Allison.
Mod Pathol, 2020 Nov 07; 34(Suppl 1). PMID: 33154551
Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients.
Jiujun Zhu, Dechuang Jiao, +4 authors, Zhenzhen Liu.
Sci Rep, 2021 Jan 16; 11(1). PMID: 33446717    Free PMC article.
Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study.
Yunju Kim, Sung Hoon Sim, +11 authors, Eun Sook Lee.
Sci Rep, 2021 Jan 14; 11(1). PMID: 33436702    Free PMC article.
Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches.
Marija Ban, Branka Petrić Miše, Eduard Vrdoljak.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447229    Free PMC article.
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Xingfa Huo, Jinming Li, +5 authors, Jiuda Zhao.
BMC Cancer, 2021 Jan 21; 21(1). PMID: 33468087    Free PMC article.
Liquid biopsy enters the clinic - implementation issues and future challenges.
Michail Ignatiadis, George W Sledge, Stefanie S Jeffrey.
Nat Rev Clin Oncol, 2021 Jan 22; 18(5). PMID: 33473219
A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy.
Dong Song, Xiaxia Man, +3 authors, Ye Du.
Front Oncol, 2021 Jan 21; 10. PMID: 33469514    Free PMC article.
Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development and Evaluation) recommendation by the Italian Association of radiation therapy and Clinical Oncology (AIRO).
Lorenza Marino, Valentina Lancellotta, +9 authors, Rolando M D'Angelillo.
Breast, 2021 Jan 15; 55. PMID: 33445150    Free PMC article.
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes.
Lucie Laot, Enora Laas, +12 authors, Anne-Sophie Hamy.
Cancers (Basel), 2021 Jan 10; 13(2). PMID: 33418983    Free PMC article.
The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
Roberto A Leon-Ferre, Tina J Hieken, Judy C Boughey.
Ann Surg Oncol, 2021 Jan 25; 28(4). PMID: 33486641
The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
I Whitehead, G W Irwin, +17 authors, NeST Study Research Collaborative.
BMC Cancer, 2021 Jan 24; 21(1). PMID: 33482770    Free PMC article.
Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy.
Emanuela Ferraro, Monica N Fornier.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490206    Free PMC article.
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
Mirella L Altoe, Kevin Kalinsky, +9 authors, Andreas H Hielscher.
Breast Cancer Res, 2021 Feb 02; 23(1). PMID: 33517909    Free PMC article.
Lobular Breast Cancer: A Review.
Natalie Wilson, Alastair Ironside, Anna Diana, Olga Oikonomidou.
Front Oncol, 2021 Feb 02; 10. PMID: 33520704    Free PMC article.
Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Miao Liu, Siyao Liu, Liu Yang, Shu Wang.
BMC Cancer, 2021 Feb 06; 21(1). PMID: 33541289    Free PMC article.
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Mei Zhou, Prabhakar Pitta Venkata, +13 authors, Gangadhara R Sareddy.
Breast Cancer Res Treat, 2020 Oct 16; 185(2). PMID: 33057995
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
Janine M Simons, Julien G Jacobs, +9 authors, Ernest J T Luiten.
Breast Cancer Res Treat, 2020 Oct 20; 185(2). PMID: 33073303    Free PMC article.
Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer.
Zhen Wang, Lei Liu, +4 authors, Sheng Zhang.
Front Oncol, 2021 Feb 09; 10. PMID: 33552956    Free PMC article.
Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Yanyu Zhang, Yaotian Zhang, +9 authors, Na Zhang.
J Oncol, 2021 Feb 11; 2021. PMID: 33564308    Free PMC article.
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Elena Fountzila, Michail Ignatiadis.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574892    Free PMC article.
Learning from clinical trials of neoadjuvant checkpoint blockade.
Judith M Versluis, Georgina V Long, Christian U Blank.
Nat Med, 2020 Apr 11; 26(4). PMID: 32273608
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study.
Zhiying Shao, Shalini Chaudhri, +2 authors, Daniel Rea.
Oncol Res, 2016 May 01; 23(6). PMID: 27131315    Free PMC article.
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
Bora Lim, Juhee Song, +9 authors, Vicente Valero.
Oncologist, 2020 Nov 04; 26(2). PMID: 33140515    Free PMC article.
Immunotherapeutic strategies in breast cancer: A clinical update.
Jennifer Q Zhang, George Plitas.
J Surg Oncol, 2020 Nov 07; 123(3). PMID: 33155281    Free PMC article.
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments.
Heather R Greene, Lee S Schwartzberg.
J Adv Pract Oncol, 2021 Feb 19; 11(3). PMID: 33598323    Free PMC article.
Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?
Angelena Crown, Mithat Gonen, Tiana Le, Monica Morrow.
Ann Surg Oncol, 2020 Sep 23; 28(3). PMID: 32959140    Free PMC article.
Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
Vivian Man, Ava Kwong.
Breast Cancer Res Treat, 2021 Feb 22; 186(3). PMID: 33611665
Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
M E Tesch, S K Chia, C E Simmons, N LeVasseur.
Breast Cancer Res Treat, 2021 Feb 22; 187(1). PMID: 33611678
Is there a correlation between miR-301a expression and neoadjuvant chemotherapy efficacy in breast cancer tissue?
Shanshan Deng, Tingyou Zhang, +8 authors, Ning Li.
Biochem Biophys Rep, 2021 Feb 23; 26. PMID: 33614999    Free PMC article.
Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer.
Taher Al-Tweigeri, Mahmoud Elshenawy, +9 authors, Adher Al Sayed.
J Oncol, 2021 Feb 26; 2021. PMID: 33628241    Free PMC article.
Concomitant use of 18F-FDG PET-CT SUVmax is useful in the assessment of Ki67 labeling index in core-needle biopsy specimens of breast cancer.
Hiroki Nakajima, Kazuma Maeno, +6 authors, Ken-Ichi Ito.
Gland Surg, 2021 Feb 27; 10(1). PMID: 33633957    Free PMC article.
Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
Zhiqiang Shi, Xueer Wang, +8 authors, Yongsheng Wang.
Gland Surg, 2021 Feb 27; 10(1). PMID: 33633973    Free PMC article.
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Amparo Garcia-Tejedor, Sergi Fernandez-Gonzalez, +19 authors, Catalina Falo.
Breast Cancer Res Treat, 2020 Oct 18; 185(3). PMID: 33068198
Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
Shiwei Liu, Shiyan Zeng, +7 authors, Purong Zhang.
Breast Cancer Res Treat, 2020 Nov 10; 185(3). PMID: 33165709
Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.
Alessandro De Vita, Chiara Liverani, +11 authors, Toni Ibrahim.
Sci Rep, 2021 Mar 05; 11(1). PMID: 33658580    Free PMC article.
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Mei-Yin C Polley, Roberto A Leon-Ferre, +17 authors, Matthew P Goetz.
Breast Cancer Res Treat, 2021 Jan 04; 185(3). PMID: 33389409    Free PMC article.
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Otto Metzger Filho, Daniel G Stover, +19 authors, W Fraser Symmans.
JAMA Oncol, 2021 Feb 19; 7(4). PMID: 33599688    Free PMC article.
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Serafin Morales Murillo, Ariadna Gasol Cudos, +6 authors, Antonieta Salud Salvia.
Breast, 2021 Feb 19; 56. PMID: 33601299    Free PMC article.
Recent advances in neoadjuvant therapy for breast cancer.
David A Potter, César A Herrera-Ponzanelli, +5 authors, Douglas Yee.
Fac Rev, 2021 Mar 05; 10. PMID: 33659921    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
Ilana Usiskin, Fangyong Li, +2 authors, Tara Sanft.
Breast Cancer Res Treat, 2020 Oct 31; 186(1). PMID: 33125620
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art.
Florence Lerebours, Luc Cabel, Jean-Yves Pierga.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33670042    Free PMC article.
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
Beatriz Grandal, Manon Mangiardi-Veltin, +12 authors, Anne-Sophie Hamy.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33670162    Free PMC article.
Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer.
Gabriela Candás, Alejandra García, +11 authors, Juan Luis Uriburu.
Ecancermedicalscience, 2021 Mar 09; 15. PMID: 33680076    Free PMC article.
Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Carolin Müller, Gilda Schmidt, +4 authors, Stephanie Juhasz-Böss.
Arch Gynecol Obstet, 2021 Mar 11;. PMID: 33689016
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
R F D van la Parra, A B Tadros, +7 authors, H M Kuerer.
Br J Surg, 2018 Feb 22; 105(5). PMID: 29465744    Free PMC article.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Yuan, Jin Sun Lee, +19 authors, Joanne Mortimer.
Oncologist, 2020 Oct 25; 26(3). PMID: 33098195    Free PMC article.
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.
R Caparica, M Bruzzone, +4 authors, E de Azambuja.
ESMO Open, 2021 Feb 28; 6(2). PMID: 33639601    Free PMC article.
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
J Delgado, C Vleminckx, +5 authors, F Pignatti.
ESMO Open, 2021 Mar 02; 6(2). PMID: 33647599    Free PMC article.
Treatment response correlation between primary tumor and axillary lymph nodes after neoadjuvant therapy in breast cancer: a retrospective study based on real-world data.
Yu Wang, Longfei Li, +5 authors, Shengchun Liu.
Gland Surg, 2021 Mar 13; 10(2). PMID: 33708548    Free PMC article.
Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Paula Cabrera-Galeana, Enrique Soto-Perez-de-Celis, +7 authors, Juan Enrique Bargallo-Rocha.
Oncologist, 2020 Apr 11; 25(12). PMID: 32275801    Free PMC article.
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
Yukiko Tokuda, Masahiro Yanagawa, +9 authors, Noriyuki Tomiyama.
Breast Cancer Res Treat, 2021 Mar 18;. PMID: 33730265
Quantitative analysis of contrast enhanced spectral mammography grey value for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy.
Dong Xing, Ning Mao, +3 authors, Yongbin Lv.
Sci Rep, 2021 Mar 17; 11(1). PMID: 33723322    Free PMC article.
Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.
Jin Hong, Yiwei Tong, +2 authors, Kunwei Shen.
Ther Adv Med Oncol, 2021 Mar 20; 13. PMID: 33737963    Free PMC article.
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients.
Huijuan Dai, Xiaonan Sheng, +8 authors, Jinsong Lu.
Front Oncol, 2021 Mar 20; 11. PMID: 33738251    Free PMC article.
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
Ipshita Prakash, Samantha M Thomas, +4 authors, Oluwadamilola M Fayanju.
Breast Cancer Res Treat, 2020 Nov 19; 186(2). PMID: 33206290    Free PMC article.
Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Hsu-Huan Chou, Wei-Shan Chung, +7 authors, Shin-Cheh Chen.
BMC Surg, 2021 Mar 25; 21(1). PMID: 33757489    Free PMC article.
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Sung Gwe Ahn, Seon-Kyu Kim, +5 authors, Charles M Perou.
Breast Cancer Res Treat, 2021 Mar 27;. PMID: 33770313
Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.
Jiaqiang Zhang, Chang-Yun Lu, Ho-Min Chen, Szu-Yuan Wu.
JAMA Netw Open, 2021 Mar 13; 4(3). PMID: 33710293    Free PMC article.
Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis.
S Peleg Hasson, M R Brezis, +3 authors, A Sonnenblick.
ESMO Open, 2021 Mar 19; 6(2). PMID: 33735801    Free PMC article.
Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.
Benjamín Walbaum, Francisco Acevedo, +15 authors, César Sánchez.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777171    Free PMC article.
Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital.
Francisco Acevedo, Militza Petric, +14 authors, Raúl Martinez.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777178    Free PMC article.
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Aidan C Li, Jing Zhao, +5 authors, Anil V Parwani.
Breast Cancer Res Treat, 2020 Feb 01; 180(2). PMID: 32002765    Free PMC article.
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Miguel Martin, Rocio Ramos-Medina, +20 authors, Sara Lopez-Tarruella.
Sci Rep, 2021 Mar 31; 11(1). PMID: 33782404    Free PMC article.
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
E Ortolan, V Appierto, +14 authors, S Di Cosimo.
ESMO Open, 2021 Mar 21; 6(2). PMID: 33743331    Free PMC article.
Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy.
Hiroko Nogi, Makiko Kamio, +3 authors, Hiroshi Takeyama.
Mol Clin Oncol, 2021 Apr 06; 14(5). PMID: 33815791    Free PMC article.
Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease.
Ryungsa Kim, Takanori Kin.
Front Oncol, 2021 Apr 06; 11. PMID: 33816282    Free PMC article.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
José Bines, Emma Clark, +14 authors, Jennifer A Petersen.
Br J Cancer, 2021 Apr 09;. PMID: 33828257
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Semir Bešlija, Zdenka Gojković, +33 authors, Rajna Stanušić.
Bosn J Basic Med Sci, 2020 May 18; 21(2). PMID: 32415816    Free PMC article.
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer.
Tara Hyder, Saveri Bhattacharya, +2 authors, Adam M Brufsky.
Breast Cancer (Dove Med Press), 2021 Apr 10; 13. PMID: 33833568    Free PMC article.
Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
Maitri Kalra, Yan Tong, +8 authors, Kathy D Miller.
NPJ Breast Cancer, 2021 Mar 24; 7(1). PMID: 33753748    Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, +10 authors, Alexandr Poprach.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33808149    Free PMC article.
Update on systemic treatment for newly diagnosed inflammatory breast cancer.
Sudpreeda Chainitikun, Sadia Saleem, +2 authors, Naoto T Ueno.
J Adv Res, 2021 Apr 13; 29. PMID: 33842000    Free PMC article.
An immunohistochemical panel of three small ubiquitin-like modifier genes predicts outcomes of patients with triple-negative breast cancer.
Yuxiang Lin, Qingshui Wang, +7 authors, Chuangui Song.
Gland Surg, 2021 Apr 13; 10(3). PMID: 33842251    Free PMC article.
Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors.
Jian Zhang, Linhai Xiao, +3 authors, Ke Wang.
Ann Surg Oncol, 2020 Oct 24; 28(5). PMID: 33095360
Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
XinJie Chen, Yu Gao, +4 authors, XiaoMin Wang.
J Cancer, 2021 Apr 16; 12(9). PMID: 33854624    Free PMC article.
Photoacoustic Computed Tomography of Breast Cancer in Response to Neoadjuvant Chemotherapy.
Li Lin, Xin Tong, +3 authors, Lihong V Wang.
Adv Sci (Weinh), 2021 Apr 16; 8(7). PMID: 33854889    Free PMC article.
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Mark Jesus M Magbanua, Wen Li, +14 authors, Laura van 't Veer.
NPJ Breast Cancer, 2021 Mar 27; 7(1). PMID: 33767190    Free PMC article.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Monika Graeser, Simone Schrading, +19 authors, Ulrike Nitz.
Int J Cancer, 2021 Feb 04;. PMID: 33533487    Free PMC article.
Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer.
Allison P Drain, Nastaran Zahir, +11 authors, Valerie M Weaver.
J Exp Med, 2021 Apr 07; 218(5). PMID: 33822843    Free PMC article.
Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis.
Jie Zhang, Yushuai Yu, +6 authors, Chuangui Song.
Ther Adv Med Oncol, 2021 Apr 20; 13. PMID: 33868462    Free PMC article.
Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ming Fan, Hang Chen, +5 authors, Lihua Li.
Front Mol Biosci, 2021 Apr 20; 8. PMID: 33869279    Free PMC article.
Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
Yoriko Hasegawa, Nobuaki Matsubara, +7 authors, Toru Mukohara.
In Vivo, 2021 Feb 25; 35(2). PMID: 33622900    Free PMC article.
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Yongsheng Jia, Krithika N Kodumudi, +17 authors, Brian J Czerniecki.
Mol Ther, 2021 Jan 08; 29(4). PMID: 33412308    Free PMC article.
SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer.
Weipeng Zhao, Linlin Sun, +4 authors, Zhongsheng Tong.
Sci Rep, 2021 Apr 28; 11(1). PMID: 33903614
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Santiago González-Santiago, Cristina Saura, +9 authors, José Ignacio Chacón.
Breast Cancer Res Treat, 2020 Sep 03; 184(2). PMID: 32876911